Issuu on Google+

ANNUAL REPORT Department of Medicine July 1, 2010 to June 30, 2011


TABLE OF CONTENTS Our Staff – Department of Medicine ……………………………………………………………………… 2 Message from the Physician-in-Chief: Dr. Tom Stewart ………………………………………. 3 Overview of the Department …………………………………………………………………………………

4

Department of Medicine Strategic Plan – Accomplishments …………………………………

6

Promotions …………………………………………………………………………………………………………….

9

New Appointments …………………………………………………………………………………………………

9

Major Awards and Accomplishments …………………………………………………………………….

10

Department of Medicine Research Awards ……………………………………………………………

11

UHN/MSH Mimi and Charles Hollenberg Research Competition Award Winners ….

12

UHN/MSH Teaching Awards ……………………………………………………………………………………

13

Joint Department of Medicine Newsletter ……………………………………………………………

14

Research Report – Grants and Publications ………………………………………………………….

15

Department of Medicine Annual Report 2010-2011

1


OUR STAFF – DEPARTMENT OF MEDICINE (As of July 31, 2011) Cardiology Dr. Gary Newton* Dr. Eduardo Azevedo Dr. Alan Barolet Dr. Jack Colman Dr. John Floras Dr. Jewel Gold Dr. Susanna Mak Dr. Michael McDonald Dr. Gillian Nesbitt Dr. John Parker Dr. Zion Sasson Dr. Robert Wald Endocrinology Dr. Gary Lewis* Dr. Jerald Bain Dr. Daniel Drucker Dr. George Fantus Dr. Denice Feig Dr. Jacqueline James Dr. Ravi Retnakaran Dr. Paul Walfish Dr. Bernard Zinman Gastroenterology Dr. Hillary Steinhart* Dr. Ken Croitoru Dr. Victor Feinman Dr. Gordon Greenberg Dr. Alvin Newman Dr. Geoff Nguyen Dr. Mark Silverberg

General Internal Medicine Dr. Howard Abrams* Dr. Allan Detsky Dr. Shital Gandhi Dr. Barry Goldlist (& Geriatrics) Dr. Ken Locke Dr. Matthew Morgan Dr. Mirek Otremba Dr. Yash Patel Dr. Samir Sinha (& Geriatrics) Dr. Christine Soong Hematology/Oncology Dr. Malcolm Moore* Dr. Dominick Amato Dr. Martin Blackstein Dr. Ronald Burkes Dr. Christine Elser Dr. Pamela Goodwin Infectious Diseases Dr. Conrad Liles* Dr. Michael Christian (& CC) Dr. Tony Mazzulli Dr. Kelly MacDonald Dr. Andrew Morris (& GIM) Dr. Hillar Vellend (& GIM) Nephrology Dr. Judith Miller* Dr. Alexander Logan Dr. Douglas Ryan

Neurology Dr. Vera Bril* Dr. Allan Gordon Dr. Jason Lazarou Dr. Maureen Shandling Respiratory Medicine / Critical Care Dr. John Granton* Dr. Meyer Balter Dr. Niall Ferguson (*CC) Dr. Shiphra Ginsburg Dr. Roger Goldstein (West Park) Dr. Stephen Lapinsky Dr. Sangeeta Mehta Dr. Mitra Niroumand Dr. Thomas Stewart Dr. Noe Zamel Rheumatology Dr. Jorge Sanchez-Guerrero* Dr. Zareen Ahmad Dr. Claire Bombardier Dr. Simon Carette Dr. Ed Keystone Dr. Peter Lee Dr. Heather McDonald-Blumer Dr. Shikha Mittoo Dr. Katherine Siminovitch Dr. Jerry Tenenbaum Medical Genetics Dr. Chantal Morel

*Division Head Note: this list does not include minor part-time staff

Department of Medicine Annual Report 2010-2011

2


MESSAGE FROM THE PHYSICIAN-IN-CHIEF: DR. TOM STEWART It is with pleasure that I introduce the Mount Sinai Hospital Department of Medicine Annual Report for the academic year 2010-2011. This was another very successful year for the Department of Medicine, with our members achieving many accomplishments and accolades. Over the past year, the Department welcomed several new members, including Samir Sinha (Division of Geriatrics), Christine Soong (Division of General Internal Medicine), Mathew Morgan (Division of General Internal Medicine), Gillian Nesbitt (Division of Cardiology), Philip Segal (Division of Endocrinology), and Jorge Sanchez-Guerrero (Division of Rheumatology). We extend a warm welcome to these new members of our team. I am also particularly pleased that Stephen Lapinsky and Irving Salit were promoted this academic year to full Professor. A large group of Department members were also promoted to the status of Associate Professor. Congratulations to these individuals who all make tremendous contributions to our Department on a daily basis. Many members of our Department were the recipients of prestigious awards, locally, nationally and internationally, recognizing their tremendous achievements and leadership in medicine, education and research. Congratulations to you all. I am also very pleased to announce that the deliverables outlined in the Department of Medicine Strategic Plan have been progressing as planned. Over the course of this past academic year, we have made great strides in advancing the strategic directions of our Department. In closing, I would like to thank all of our faculty and staff for your contributions, hard work and dedication. You each hold an integral role in our Department, and I look forward to our continued success. Sincerely,

Thomas Stewart Physician-in-Chief and Chief Clinical Officer

Department of Medicine Annual Report 2010-2011

3


OVERVIEW OF THE DEPARTMENT Mount Sinai Hospital’s Department of Medicine is made up of 77 full and part time medical staff based at Mount Sinai who contribute significantly to patient value by providing world-class medical care, conducting research that improves patient care and educating current and future healthcare workers and researchers. Mount Sinai’s Department of Medicine works closely with the Department of Medicine at the University Health Network – the 2 hospitals have a collaborative Department of Medicine, share 12 joint Division Heads and cross appoint 270 medical staff. They also share a practice plan which is the key driver of our successes. The University of Toronto’s Department of Medicine partners with Mount Sinai’s Department of Medicine, which serves as a clinical teaching site for the University. The Department of Medicine is also influenced by the priorities of other teaching and community hospitals, the Toronto Central Local Health Integration Network and the Ontario Ministry of Health and Long-Term Care. The mission of the Department of Medicine at Mount Sinai Hospital is to provide clinical care (on an inpatient, outpatient, and community basis), perform research, and to educate undergraduates, postgraduates, and physicians in practice, as well as other healthcare workers. The Department provides patient care in all areas of Internal Medicine and has inpatient units in four specific areas: General Internal Medicine, Cardiology, Critical Care Medicine, and Gastrointestinal Diseases. Our other divisions (Endocrinology, Hematology/Oncology, Infectious Diseases, Nephrology (including Hypertension), Neurology, Respirology, Rheumatology, Obstetrical Medicine, Dermatology, Geriatrics, and Medical Genetics) primarily provide ambulatory or consulting inpatient services. All divisions participate in all three aspects of our mission.

Department of Medicine Annual Report 2010-2011

4


Department of Medicine Annual Report 2010-2011

5


DEPARTMENT OF MEDICINE STRATEGIC PLAN - ACCOMPLISHMENTS In May 2010, the Mount Sinai Hospital Department of Medicine released its five year Strategic Medical Plan, which is built on underlying assumptions that support the Hospital’s strategic focus of Putting Patients First. These assumptions support broad strategic directions in five areas: Patient Care, Research, Education, Partnerships and Leadership. Each strategic direction includes clear objectives, along with explicit actions and detailed deliverables for 2009/10 to 2013/14 (June 1-May 31). Since its launch, the deliverables and actions within each of the five strategic directions have been progressing as planned and many accomplishments have been achieved this past academic year; a summary, highlighting key achievements is listed below. I. STRATEGIC OBJECTIVE: PATIENT CARE Recruitment:      

Dr. Gillian Nesbitt, Clinical Teacher, was recruited and started in July 2010 and is supervising the core UofT rotation program in echocardiography at Mount Sinai Hospital. Dr. Phillip Segal, Clinical Teacher, in Mount Sinai Hospital’s Head and Neck Centre was recruited. Dr. Samir Sinha, Director of Geriatrics at Mount Sinai Hospital and University Health Network, joined the Department in September 2010. Dr. Anne Grandmaison, Clinical Associate, joined the Division of Oncology and Haematology in March 2010. Dr. Jorge Sanchez-Guerrero, joined the Division of Rheumatology in July 2011 as the Division Head at Mount Sinai Hospital and University Health Network. Dr. Christine Soong joined the Division of General Internal Medicine in January 2011 as a Clinician Teacher, based at Mount Sinai Hospital. As of March 28th, Christine launched the Hospitalist-Orthopedic Team to provide comprehensive medical and surgical care to hip fracture patients. Dr. Matthew Morgan joined the Division of General Internal Medicine in March 2011. He has also assumed the new administrative position of Senior Clinical Director, Special Projects, including oversight of the Quality and Performance Measurement Team.

Initiatives:  

Cardiology: As of September, the Toronto General Hospital and Mount Sinai Hospital Heart Failure programs have been merged to create Canada’s largest Heart Failure program in terms of staff, patients seen and academic output. Dermatology: As of October, Drs. Cheryl Rosen and Sanjay Siddha hold a Dermatology outpatient clinic on Fridays out of the Rebecca MacDonald Centre located in 60 Murray Street.

Department of Medicine Annual Report 2010-2011

6


    

General Internal Medicine: Dr. Shital Gandhi and Anita Low have been leading Mount Sinai Hospital in a Patient Navigator one year pilot project since July 2010. Since July, two Patient Navigators (Nathan Duyck and David Wells) have been working with GIM Teams A and C, nursing and allied health professionals to help coordinate patient care in a timely and efficient manner with a focus on the patient, staff and physician experience. As of May 1st, the Patient Navigators have recently transitioned to work with GIM Teams B and D, with the hopes of rolling out to other areas in the Hospital. Geriatrics: Mount Sinai Hospital’s Ben and Hilda Katz Acute Care for Elders Unit (ACE) opened on April 18th 2011 with 17 south being converted to a 28-bed ACE unit. Gastroenterology: The Division has conducted an external review to develop a vision and operational plan for a patient-centred, comprehensive, interdisciplinary outpatient service. Haematology: Mount Sinai Hospital has been integrated into the general Haematology consult service with Toronto Western, Toronto General and Princess Margaret Hospitals. Antibiotic stewardship best practices have been successfully integrated into several areas of the Hospital under Dr. Andrew Morris’ leadership. In the fall of 2010, the Mount Sinai Hospital Effective and Efficient Utilization Committee (EEUC) was formed, whose purpose is to formalize and implement guidelines outlining appropriate use of treatments and interventions, including but not limited to medical imaging procedures, laboratory tests and drug use.

II. STRATEGIC OBJECTIVE: RESEARCH 

A Research Committee for the MSH Department of Medicine was established in January 2010 with resources in the current academic year to support the research objectives outlined in the Strategic Medical Plan. Dr. John Floras has been appointed as the Department of Medicine Research Lead, who chairs the Department’s Research Committee. This Committee is working to strengthen collaborative research efforts between the Department and the Samuel Lunenfeld Research Institute. The Department of Medicine research activities have been profiled at the Mount Sinai Hospital Research Committee of the Board – Inflammatory Bowel Disease, Obstetric Medicine and Cardiology presentations have been made to date.

III. STRATEGIC OBJECTIVE: EDUCATION    

Simulation training in advanced cardiac life support was provided for all senior residents. New leadership for PREPS program was secured. In collaboration with Mount Sinai Hospital, shared administrative guidance with Surgical Skills Centre and Simulation Centre was established. Dr. Jacqueline James was appointed Vice President, Education, integrating the Department’s education activities with those of the Hospital.

Department of Medicine Annual Report 2010-2011

7


IV. STRATEGIC OBJECTIVE: PARTNERSHIPS 

With the purpose of engaging in a social outreach initiative, Dr. Jason Lazarou (Staff Neurologist) and Dr. Sasha High (Resident and CMR for July 2011) visited Guatemala, Central America in November 2010 with a medical and dental team as a part of Feed the Children. They have prepared a report outlining their experiences and potential partnership opportunities.

V. STRATEGIC OBJECTIVE: LEADERSHIP  

A group of Department of Medicine physicians have participated in leadership development training at the University of Toronto (Drs. Gandhi, Lapinsky, Otremba, Barolet and Morris). The Department of Medicine Web CV program was implemented to facilitate easy database management.

Department of Medicine Annual Report 2010-2011

8


PROMOTIONS The following group of physicians received promotional awards effective July 1, 2010. Promoted to Professor Dr. Stephen Lapinsky (MSH) Dr. Irving Salit (UHN) Promoted to Associate Professor Dr. Mark Silverberg (MSH) Dr. Camilla Zimmerman (UHN) Dr. Natasha Leighl (UHN) Dr. Douglas Ing (UHN) Dr. Susan Fox (UHN) Dr. Diego Delgado (UHN) Dr. Anil Chopra (UHN) Dr. Maria Cino (UHN)

NEW APPOINTMENTS Dr. Jacqueline James was appointed as Vice President of Education, Mount Sinai Hospital. As a member of the Senior Management Team, in this position, Dr. James will be responsible for advancing the development of existing and innovative educational programs for health professionals in alignment with the strategic goals of the Hospital. Dr. Mark Silverberg was appointed as a Scientist within the Samuel Lunenfeld Research Institute in recognition of his abilities and achievements in the field of Inflammatory Bowel Disease. Dr. Candice Silversides was appointed as the Head of Mount Sinai Hospital’s Obstetric Medicine Program. With the support of the Department of Medicine and Obstetrics, Dr. Silversides and Mount Sinai Hospital are committed to developing an internationally pre-eminent Obstetric Medicine program with the mission to improve the care of pregnant women with medical disorders and their children and advance the field of Obstetric Medicine through innovation and collaborative research.

Department of Medicine Annual Report 2010-2011

9


MAJOR AWARDS AND ACCOMPLISHMENTS Dr. John Floras was invited by the CIHR Institute of Circulatory and Respiratory Health to deliver the 2010 Distinguished Lecture in Cardiovascular Science as part of the Canadian Cardiovascular Congress’ October meeting. Dr. John Floras was also the recipient of the University of Toronto Department of Medicine Researcher of the Year Award, honouring his sustained excellence as a scientist and role model over the course of his career. Dr. Shiphra Ginsburg was the recipient of the prestigious Stemmler Fund Award in recognition of her international leadership in education. This Award is issued by the National Board of Medical Examiners in the US and is highly competitive. Dr. Barry Goldlist was the recipient of the 2010 Canadian Geriatrics Society’s Ronald Cape Distinguished Service Award for his contributions to the development of Geriatrics in Canada. Dr. John Granton was awarded the Wightman-Berris Academy’s Anderson Award in the ‘Extraordinary Contribution to Education’ category. The Anderson Award recognizes the importance of educational innovation, administration and leadership. Dr. Kenneth Locke was the winner of the Society of General Internal Medicine 2010 Precourse Award for the precourse that received the highest overall mean rating from attendees – “How to Enrich Education with Web 2.0: Wikis, Blogs and Beyond for the Clinician Educator.” Dr. Heather McDonald-Blumer was awarded a 2010 Program Director of the Year Award from the Royal College of Physicians and Surgeons of Canada for her contributions to education, program innovation and development. She was also one of the recipients of the University of Toronto, Faculty of Medicine’s Education Development Fund for fostering the professionalism of clinical faculty - a qualitative needs assessment and pilot project conducted in Internal Medicine. In addition, Dr. McDonald-Blumer was the recipient of the 2011 William Goldie Prize and Travel Award. Dr. Geoffrey Nguyen’s application for his second 5-year CIHR New Investigator Award was approved and should be effective through to February 2017. Dr. Yash Patel was one of the recipients of the 2011 PAIRO Excellence in Clinical Teaching Award for the University of Toronto, honouring the essential role that he plays in the training of new physicians.

Department of Medicine Annual Report 2010-2011

10


DEPARTMENT OF MEDICINE RESEARCH COMMITTEE AWARDS In this past academic year, the Mount Sinai Hospital Department of Medicine Research Committee has initiated several merit based competitions for partial support of a small group of summer students, graduate students and post-doctoral fellows proposing to conduct research aligned with the Department’s research themes and strategic foci, and in particular translational research or research advancing the theme of ‘personalized medicine’. Also, funds were made available for pilot projects or bridge funding for continuation of ongoing research similarly aligned. This was an exciting new direction for the Department, designed to stimulate collaborative research across our campus. The 2010-2011 Award recipients are listed below: AWARD CATEGORY Graduate Studentships ($15,000 each) Open Competition (Fall & Spring, $25,000 each)

AWARD RECIPIENTS    

Summer Studentships ($2,000 each)

 

ASCI Trainee Observership ($2,000 each) Postdoctoral Fellowship ($15,000 each)

   

Michal Sibony, supervised by Dr. Mark Silverberg Anu Shah, supervised by Dr. George Fantus Fall: Dr. Katherine Siminovitch, in support of the study of a personal medical network to guide genomic application in the clinic Spring: Dr. George Fantus, in support of an animal and human study of Src activation and diabetic nephropathy Catherine Chan, supervised by Dr. Ken Croitoru Ameya Bopardikar and Peini Yin, supervised by Dr. Samir Sinha Davide Cina, supervised by Dr. Sue Quaggin Joseph Ly, supervised by Dr. Sue Quaggin Dr. David Kevan, supervised by Dr. Mark Silverberg and Dr. Ken Croitoru Dr. Shireen Brewster, supervised by Dr. Ravi Retnakaran and Dr. John Floras

Department of Medicine Annual Report 2010-2011

11


UHN/MSH MIMI AND CHARLES HOLLENBERG RESEARCH COMPETITION AWARD WINNERS CATEGORY 1: Case Report / Series / Brief Clinical Investigation 1. First Prize: $1000 Student: Travis Murdoch Supervisor: Mark Silverberg 2. Second Prize: $500 Student: Taryn Simms Supervisor: Douglas Bradley 3. Third Prize: $250 Student: Jerome Leis Supervisor: Wayne Gold CATEGORY 2: Clinical Investigation or Clinical Epidemiology 1. First Prize: $1000 Student: Matthew Burke Supervisor: Leanne Casaubon 2. Second Prize: $500 Student: Morgan Rosenberg Supervisor: Geoffrey Nguyen 3. Third Prize: $250 Student: Derek MacFadden Supervisor: Douglas Lee CATEGORY 3: Research Projects of a Mechanistic Nature 1. First Prize: $1000 Student: Safina Ali Supervisor: Daniel Drucker 2. Second Prize: $500 Student: Lihi Eder Supervisor: Dafna Gladman 3. Third Prize: $250 Student: Constance Finney Supervisor: Kevin Kane Department of Medicine Annual Report 2010-2011

12


UHN/MSH TEACHING AWARDS Sopman Humanitarian Award (UHN)

Robert Goldberg

PGY1

Juan Duero Posada PGY2 Jerome Leis PGY3

Barnet Berris Clinical Acumen Resident Award (MSH) Janice Kwan

PGY2

Outstanding Housestaff Award

Derek MacFadden Lee Fidler Grace Leung Jonathan Ailon Jessica Liu Adrian Sacher Katherine Stanley Seema Marwaha Jer么me Leis

PGY1 PGY1 PGY1 PGY2 PGY2 PGY2 PGY3 PGY3 PGY3

Excellence in Teaching Award Postgraduate

Mitra Niroumand (MSH) Mirek Otremba (MSH) Alan Barolet (MSH)

Excellence in Teaching Award Undergraduate

Katina Tzanetos (UHN) Lisa Richardson (UHN) Wayne Gold (UHN)

Excellence in Teaching Award New Faculty

Michael McDonald (MSH) David Frost (UHN) Shane Shapera (UHN)

Scott-Vellend Award Sustained Excellence in Teaching

Rodrigo Cavalcanti (UHN)

Teacher of the Year Award

Heather Ross (UHN)

Chief Medical Resident Award Outstanding Leader, Educator and Role Model

Woganee Filate Larry Jacobs Kerry Thompson

Department of Medicine Annual Report 2010-2011

13


JOINT DEPARTMENT OF MEDICINE NEWSLETTER To facilitate ongoing communication across the Department, both at Mount Sinai Hospital and University Health Network, the Joint Department of Medicine Newsletter was launched this past academic year. This is an electronic newsletter, which is issued quarterly and is intended to provide members of the Department with current information about departmental activities, including key developments and achievements, member contributions and upcoming events. Please click on the following links to access our previous issues: Fall/Winter 2010 New Recruits: http://intranet.uhn.ca/departments/medicine/newsletter/story1.asp Key Developments: http://intranet.uhn.ca/departments/medicine/newsletter/story2.asp Member Spotlight: http://intranet.uhn.ca/departments/medicine/newsletter/story3.asp Achievements: http://intranet.uhn.ca/departments/medicine/newsletter/story4.asp Upcoming Events: http://intranet.uhn.ca/departments/medicine/newsletter/story5.asp Spring/Summer 2011 New Recruits: http://intranet.uhn.ca/departments/medicine/newsletter/Spring2011/Story1.asp Key Developments: http://intranet.uhn.ca/departments/medicine/newsletter/Spring2011/Story2.asp Member Spotlight: http://intranet.uhn.ca/departments/medicine/newsletter/Spring2011/Story3.asp Achievements: http://intranet.uhn.ca/departments/medicine/newsletter/Spring2011/Story4.asp Upcoming Events: http://intranet.uhn.ca/departments/medicine/newsletter/Spring2011/Story5.asp

Department of Medicine Annual Report 2010-2011

14


RESEARCH REPORT We have included a list of grants and publications of the members of our Department for the 2010 calendar year. As you can see, many members of the Department achieved considerable success in research in the past year.

Department of Medicine Annual Report 2010-2011

15


Howard Abrams General Internal Medicine Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Wong HJ, Morra D, Caesar M, Carter MW, Abrams H. Understanding hospital and emergency department congestion: an examination of inpatient admission trends and bed resources. CJEM 2010;12(1):18-26 Wu RC, Morra D, Quan S, Lai S, Zanjani S, Abrams HB, Rossos P. The Use of Smartphones for Clinical Communication on Internal Medicine Wards. Journal of Hospital Medicine 2010; 0(0);

Department of Medicine Annual Report 2010-2011

16


Meyer Balter Respirology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Marciniuk DD, Brooks D, Butcher S, Debigare R, Dechman G, Ford G, Pepin V, Reid D, Sheel AW, Stickland MK, Todd DC, Walker SL, Aaron SD, Balter M, Bourbeau J, Hernandez P, Maltais F, O'Donnell DE, Bleakney D, Carlin B, Goldstein R, Muthuri SK; Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease-practical issues: a CanadianThoracic Society Clinical Practice Guideline.Can Respir J. 2010;17:159-168. Detsky ME, Balter MS, Sridhar SK, Granton J. Clinical problem-solving. Under pressure. N Engl J Med. 2010;362:449-454.

NON PEER REVEIEWED Moayedi Y, Balter MS. Lung attacks: Why you should care about COPD exacerbations. A Focus on COPD 2010;1(3):9-13. Venos ES, Balter MS. The fire inside: the importance of systemic inflammation in COPD. A Focus in COPD 2010;1(4):4-7.

Department of Medicine Annual Report 2010-2011

17


Martin Blackstein Hematology/Oncology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J, O'Sullivan B, Catton C, Greenberg M, Blackstein M. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010 Jul 1;116(13):3189-94. Klieb HB, Duchnay M, Skeete D, Leong IT, Blackstein ME. Painful palatal swelling. Lancet. 2010 Apr 3;375(9721):1224. PubMed PMID: 20362816. Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer. 2010 Jul 26. PubMed PMID: 20661913. M. E. Blackstein, C. L. Corless, K. V. Ballman, C. Antonescu, C. Blanke, G. D. Demetri, M. Von Mehren, R. G. Maki, P. W. Pisters, R. P. DeMatteo. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001.

C. L. Corless, K. V. Ballman, C. Antonescu, C. D. Blanke, M. E. Blackstein, G. D. Demetri, M. von Mehren, R. G. Maki, P. W. Pisters, R. P. DeMatteo, Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. ASCO General Meeting Oral Presentation Chicago June 2010: J Clin Oncol 28:7s, 2010

M. Chacon, P. Reichardt, J. Gu, T. Nishida, C. H. Barrios, J. Blay, A. Reichardt, M. E. Blackstein, P. G. Casali, Y. Kang. The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary. ASCO General Meeting Poster Presentation Chicago June 2010:

Department of Medicine Annual Report 2010-2011

18


Claire Bombardier Rheumatology External Research Grants Prepared July 2011 Research Area Multiple Studies Across the IWH Research Agenda Canadian Foundation for Innovation Leaders Opportunity Fund (Canada Research Chair Stream) Cochrane Collaboration Back Review Group: Systematic Reviews of the Scientific Literature on Spinal Disorders Centre of Research Expertise in Improvement of Disability Outcomes Knowledge Synthesis and Transition by the Cochrane Collaboration in Canada Determinants of Risk and Outcome in Inflammatory Arthritis A prospective controlled study of the Real-World Effectiveness of Biologic Response Modifying Drugs in Adults with Rheumatoid Arthritis

Role

Granting Agency

Funding

Period

Co-PI

Institute for Work and Health, Toronto

$6,900,000

1991 - 2012

PI

CFI

$390,903

2009 -2014

Co-Investigator

Institute for Work and Health, Toronto

$83,000/yr

1995 – 2012

Co-Investigator

Workplace Safety and Insurance Board Research Advisory Council

$2,000,000

2005 - 2010

Co-Investigator

CIHR

$7,804,937

2005 - 2010

Co-Investigator

CIHR

$2,000,000

2007 – 2012

PI

CIHR

$268,138

2007 – 2010

Department of Medicine Annual Report 2010-2011

19


Claire Bombardier Research Area Effectiveness and Optimal Use of Biologic Response Modifying Drugs (BMRs) for the Treatment of Rheumatoid Arthritis (RA) in Ontario Development of a Fibromyalgia Responder Index Multiple Studies across Clinical Decision Making and Health Care Division UHN Advanced Therapeutics Research Platform Government of Canada, Canada Research Chair in Knowledge Transfer for Musculoskeletal Care, Tier I Award (Renewal)

Role

Granting Agency

Funding

Period

PI

Ministry of Health and Long-Term Care, Drug Innovation Fund

$700,000

2008 - 2011

Consultant

NIAMS R01

$175,000 USD/yr

2007 - 2010

PI

Canadian Arthritis Network

$100,000/yr

2008 - 2013

Co - Investigator

Canadian Foundation for Innovation

$119,000,000

2008 - 2013

PI

CIHR

$200,000/yr

2009 – 2016

Department of Medicine Annual Report 2010-2011

20


Claire Bombardier Rheumatology Publications for 2010 PEER REVIEWED Journal Articles Katchamart W, Bourré-Tessier J, Donka T, Drouin J, Rohekar G, Bykerk VP, Haraoui B, Leclerq S, Mosher DP, Pope JE, Shojania K, Thomson J, Thorne JC, Bombardier C; the Canadian 3e Initiative Consensus Group. Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. J Rheumatol. 2010 Jul; 37(7): 1422-1430. Katchamart W, Bombardier C. Systemic Monitoring of Disease Activity using an Outcome Measure Improves RA. J Rheumatol. 2010 Jul; 37(7): 1411-1415. Gossec L, Bijlsma JW, Bombardier C, Canhão H, Devlin J, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, MartÃn-Mola EM, Mielants H, Müller-Ladner U, Ostergaard M, Pereira IA, Ramos-Remus C, Zochling J, Dougados M. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. Ann Rheum Dis. 2010 May 14. Dionne CE, Le Sage N, Franche RL, Dorval M, Bombardier C, Deyo RA. Five questions predicted longterm, severe, back-related functional limitations: evidence from three large prospective studies. J Clin Epidemiol. 2010 May 7. Tang K, Beaton D, Lacaillle D, Gignac MA, Zhang W, Anis AH and Bombardier C. The Work Instability Scale for Rheumatoid Arthritis (RA-WIS): Does it work in osteoarthritis? Quality of Life Research 2010; Sep; 19(7):1057-1068. Epub 2010; Apr 25. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapyversus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2010 Apr 14; 4: CD008495. Review. Salliot C, Bombardier C, Saraux A, Combe B, Dougados M. Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: Results from the ESPOIR cohort. Ann Rheum Dis. 2010 Sep;69(9):1683-6. Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C. Predictors for remission in rheumatoid arthritis patients: A Systematic review. Arthritis Care Res (Hoboken). 2010 Aug;62(8):112843. Beaton DE, Tang K, , Gignac M, Lacaille D, Badley EM, Anis A, Bombardier C. Reliability, validity and responsiveness of five at-work productivity measures in persons with rheumatoid arthritis or osteoarthritis. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1): 28-37. Beaton D, Tang K, Gignac MA, Lacaillle D, Badley EM, Anis AH, and Bombardier C. Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis. Arthritis Care & Research. 2010; 62(1): 28-37. Tang K, Beaton DE, Gignac MA, Lacaille D, Zhang W, Bombardier C; and the Canadian Arthritis Network Work Productivity Group. The work instability scale for rheumatoid arthritis (RA-WIS) predicts arthritisrelated work transitions within 12 months. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1578-87.

Department of Medicine Annual Report 2010-2011

21


Claire Bombardier Busse JW, Bhandari M, Guyatt GH, Heels-Ansdell D, Mandel S, Sanders D, Schemitsch E, Swiontkowski M, Ornetta P, Wai E, Walter SD; SPRINT Investigators. Use of both Short Musculoskeletal Function Assessment questionnaire and Short Form-36 among tibial-fracture patients was redundant. J Clin Epidemiol. 2009 Nov;62(11):1210-7. Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde D, Bijlsma JWJ, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten D, Leeb BF, Losada B, Martín-Mola EM, Martinez-Osuna P, Montecucco C, Müller-Ladner U, Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2011 Jan;70(1):15-24. Zhang W, Gignac MA, Beaton D, Tang K, Anis AH; Canadian Arthritis Network Work Productivity Group. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol. 2010 Sep;37(9):1805-14. Pease C, Pope JE, Thorne C, Haraoui BP, Truong D, Bombardier C, Widdifield J, Psaradellis E, Sampalis JS, Bonner A. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. J Rheumatol. 2010 Dec;37(12):246974. Katchamart W, Faulkner A, Feldman B, Tomlinson G, Bombardier C. PubMed had a higher sensitivity than Ovid-MEDLINE in the search for systematic reviews. J Clin Epidemiol. 2010 Oct 5. Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A. Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy. Semin Arthritis Rheum. 2010 Dec 16.

Department of Medicine Annual Report 2010-2011

22


Vera Bril Neurology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

IVIG compared to PLEX for MG Corneal Nerve Fiber Density as a Biomarker of Early Neuropathy, Type 1 DM Corneal Nerve Fiber Density as a Biomarker of Early Neuropathy, Type 1 DM

Investigator Initiated Grant

Talecris

$150,000 US

2007 – 2010

Co-PI

JDRF innovation grant

$241,000 USD

2008-2010

Co-PI

JDRF innovation grant

$300,000 USD

2010-2010

$ 589,426 USD

2010-2013

Corneal Nerve Fiber Density as a Biomarker of Early Neuropathy, Type 1 DM

Co-Investigator

JDRF innovation grant

Corneal Confocal Microscopy as a Biomarker of Early Neuropathy in Type 2 Diabetes

Co-Investigator

CDA Operating Grant

$265,094

2010-2011

The Toronto JDRF Translational Centre for Clinical Research

Collaborator

JDRF International

$203,450

2010-2011

Co-PI

Talecris Biotherapeutics, Independent Research Grant

$340,555

2010-2012

Home Infusion of IVIG in CIDP Patients

Department of Medicine Annual Report 2010-2011

23


Vera Bril Neurology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung H-P, Hughes RAC, Katzberg H, Latov N, Merkies ISJ, van Doorn PA, ICE study group. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle & Nerve 42:492-497, 2010. Perkins BA, Orszag A, Ngo M, Ng E, Nwe P, Bril V. Prediction of incident diabetic neuropathy using the monofilament exam: a 4-year prospective study. Diabetes Care 33:1549-1554, 2010. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung H-P, Hughes R, Merkies I, van Doorn P. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 67:802-807, 2010 Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung H-P, Hughes RAC, Latov N, Merkies ISJ, van Doorn PA. Safety and toleratbility of immune globulin intravenous in chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 67:1082-1088, 2010. Perkins BA, Dholasania A, Buchanan RA, Bril V. Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis. Diab Med, 27:12711279, 2010. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93.

Other Perkins BA, Hertz P, Orszag A, Ng E, Nwe P, Bril V. Reliability and Validity of In-Vivo Corneal Confocal Microscopy as a Novel Small-Fiber Test for Diabetic Polyneuropathy. Neurol, 74(Suppl2):A306, 2010. Bril V, Ng E, New P, Ngo M, Leung R, Todorochko S, Orzag A, Perkins B. Clinical Utility of LDI compared with QTT for Small Fibre Neuropathy. Neurol, 74(Suppl2):A306, 2010. Navarrete C, Bril V, Balart M. Novel Acetylcholinesterase Inhibitors in myasthenia patients: a 4-year follow-up. Neurol, 74(Suppl2):A92, 2010.

Department of Medicine Annual Report 2010-2011

24


Ronald Burkes Hematology/Oncology External Research Grants Prepared July 2011 Research Area A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination with Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or 5Fluorouracil/Leucovorin with Oxaliplatin (FOLFOX4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma (The AVANT Study; Roche Protocol B017920D) Multicenter, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIB

Role

Granting Agency

Funding

Period

Co-Investigator

Hoffmann-LaRoche

$20,600

2005 - open

Co-Investigator

NCIC CTG

$10,000

2009 - open

Department of Medicine Annual Report 2010-2011

25


Ronald Burkes Research Area A double blind randomized trial of cediranib vs placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic non-small cell lung cancer (BR.29) A Randomized Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/5fluorouracil/leucovorin to the Efficacy of Oxaliplatin/5fluorouracil/leucovorin Alone in Patients with Previously Untreated Metastatic Colorectal Cancer (AMG 954)

Role

Granting Agency

Funding

Period

Co-Investigator

NCIC CTG

$8,000

2010-open

Co-Investigator

Amgen

$10,400

2006 – open

Department of Medicine Annual Report 2010-2011

26


Ronald Burkes Research Area A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 versus (Docetaxel (TAXOTERE™) in combination with Placebo in Patients with Locally Advanced or Metastatic (Stage IIIb – IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of 1st Line Anti-Cancer Therapy A Phase I Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer An international multicenter ramdomized phase III study of first-line Erlotinib followed by second-line Cisplatin + Gemcitabine versus first-line Cisplatin + Gemcitabine followed by second-line Erlotinib in advanced non small cell lung cancer (TORCH)

Role

Granting Agency

Funding

Period

Co-Investigator

Astra Zeneca

$10,500

2007 - open

Co-Investigator

Eli Lilly

$3,900 + overhead

2008 – open

Co-Investigator

EMD Serono

$14,274

2009 - open

Department of Medicine Annual Report 2010-2011

27


Ronald Burkes Research Area START – Stimulating Targeted Antigenic Responses To NSCLC: A Multi Center Phase III Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-small cell lung cancer A randomized phase III trial of oxaliplatin (oxal) plus 5fluorouracil (5FU/leucovorin (CF) with or without cetuximab (C225) after curative resection for patients with stage III colon cancer.

Role

Granting Agency

Funding

Period

Co-Investigator

EMD Serono

$14,274

2009 - open

Co-Investigator

BC Career Agency

$3,000

2010-open

Co-Investigator

NCIC CTG

$4,000 (US)

2009 – open

Department of Medicine Annual Report 2010-2011

28


Ronald Burkes Research Area A Phase 3, randomized, double blind, placebocontrolled, study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens (Agennix Incorporated/Quintiles: Protocol No. LF-0207) A DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF RECMAGE-A3 + AS15 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTABLE MAGE-A3POSITIVE NON-SMALL CELL LUNG CANCER

Role

Granting Agency

Funding

Period

Co-Investigator

Agennix

$10,284

2010-open

Co-Investigator

GSK

$22,761

2010-open

Department of Medicine Annual Report 2010-2011

29


Ronald Burkes Hematology/Oncology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Aljubran A, Leighl N, Pintilie M, Burkes R. Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer. Hematol Oncol Stem Cell Ther. 2009;2(1):265-71 Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel,Yves Humblet,György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S. Oliner, Michael Wolf, and Jennifer Gansert 2010Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer:The PRIME Study. JCO Nov 1,2010:4697-4705 Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, Inamoto A, Lillie T. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, openlabel trial. BMC Cancer. 2010 Oct 25;10:581 Eastern Canadian Colorectal Cancer Consensus: Setting the limits of resectable disease. Current Oncology 17:116-123, 2010

Department of Medicine Annual Report 2010-2011

30


Simon Carette Rheumatology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

The University Health Network Whiplash Intervention Trial

Co-PI

Aviva Insurance Company of Canada

$2,017,220

2007 - 2011

Department of Medicine Annual Report 2010-2011

31


Simon Carette Rheumatology Publications for 2010 PEER REVIEWED Case Reports Leber A, Carette S, Chapman KR, Hwang DM, Singer LG, Marras TK. A 21-year-old man with systemiconset juvenile rheumatoid arthritis, cough and progressive dyspnea. Can Respir J 2010;17: 42-4

Other American Academic of Orthopedic Surgeons. (Carette S, committee member). Non-operative treatment of Ankle Arthritis- A Technology Overview. Dec 2010 American Academy of Orthopedic Surgeons (Carette S, committee member). Surgical Treatment of Ankle Arthritis- A technology Overview. Dec 2010

Department of Medicine Annual Report 2010-2011

32


Edward Cole Nephrology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

Immune Monitoring & Minimization of Immunosuppression after Kidney Transplantation

Co-PI

NIH

$388,800

2009 - 2014

Department of Medicine Annual Report 2010-2011

33


Edward Cole Nephrology Publications for 2010 PEER REVEIEWED Journal Articles Kramer B, Charpentier B, Backman L Cole E et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. American Journal of Transplantation. 2010 Dec;10(12):2632-43. Narayan R, Cardella C, Cole E et al. Delayed graft function and the risk of death with graft function in living donor kidney transplant recipients. American Journal of Kidney Diseases 2010 Nov;56(5):961-70. Gill J, Goldberg A, Prasad G, Cole E et al. Policy statement of Canadian Society of Transplantation and Canadian Society of Nephrology on organ trafficking and transplant tourism. Transplantation. 2010 Oct 27;90(8):817-20. Keough-Ryan T, Prasad G, Hewlett T, Cole E et al. Similar outcomes for Canadian renal transplant recipients followed up in transplant centers and satellite clinics. Transplantation. 2010 Sep 27;90(6):591-6. Knoll G, Blydt-Hansen T, Campbell P, Cole E et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Kidney Diseases 2010 Aug;56(2):219-46. Humar A, Lebranchu Y, Vincenti F, Cole E et al. Expert commentary in Clinical Study Compendium on Hemophilia “Optimizing strategies to prevent cytomegalovirus disease after solid organ transplant�. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. American Journal of Transplant, 26 Mar 2010 Cole E et al. The declaration of Istanbul on organ trafficking and transplant tourism. International summit on transplant tourism and organ trafficking. Saudi Journal of Kidney Diseases and Transplantation. 2010 Jan;21(1):138-47. Tapiawala S, Tinckam K, Cardella C, Schiff J, Cattran D, Cole E, Kim S. Delayed graft function and the risk for death with a functioning graft. Journal of American Society of Nephrology. 2010 Jan;21(1):15361.

Department of Medicine Annual Report 2010-2011

34


Jack Colman Cardiology External Research Grants Prepared July 2011 Research Area Investigation of the prognostic importance of natriuretic peptides in pregnant women with heart disease: A prospective observational cohort study A Pediatric Heart Network Study (PHN): Trial of Beta Blocker Therapy (Atenolol) vs. Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals with Marfan Syndrome.

Role

Granting Agency

Funding

Period

Co - Investigator

Heart and Stroke Foundation of Ontario

$139,940

2010-2011

PI Site

US National Institutes of Health/ National Heart, Lung and Blood Institute

$2,047,004

2007 -2012

Department of Medicine Annual Report 2010-2011

35


Jack Colman Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Balint OH, Siu SC, Mason J, Grewal J, Wald R, Oechslin EN, Kovacs B, Sermer M, Colman JM, Silversides CK. Cardiac outcomes after pregnancy in women with congenital heart disease. Heart 2010;96:16561661. David Tanous, Samuel C. Siu, Jennifer Mason, Matthias Greutmann, Rachel M.Wald, John D. Parker, Mathew Sermer, Jack M. Colman, and Candice K. Silversides. B-type natriuretic peptide in pregnant women with heart disease. J. Am. Coll. Cardiol. 2010;56;1247-1253. Tobler D, Fernandes SM, Wald RM, Landzberg M, Salehian O, Siu SC, Colman JM, Sermer M, Silversides CK. Pregnancy outcomes in women with transposition of the great arteries and arterial switch operation. Am J Cardiol. 2010 Aug 1;106(3):417-20. Goldszmidt E, Macarthur A, Silversides C, Colman J, Sermer M, Siu S. Anesthetic management of a consecutive cohort of women with heart disease for labor and delivery. International Journal of Obstetric Anaesthia 2010, 19, 266-272. doi:10.1016/j.ijoa.2009.09.006. Grewal J, Siu S, Ross H, Mason J, Balint H, Sermer M, Colman J, Silversides CK. Pregnancy Outcomes in Women with Dilated Cardiomyopathy. J Am Coll Cardiol 55:45-52, 2010. Walker Melissa G, Silversides Candice K, Colman Jack M, Gandhi Shital, Kingdom John. Maternal atrial arrhythmia deteced by uterine artery Doppler. Journal of Obstetrics and Gynaecology Canada

NON-PEER REVIEWED Book Chapters Colman JM, Oechslin E, Taylor D. Glossary of Terms in Adult Congenital Heart Disease. In: Gatzoulis M, Webb GD Daubeney P, eds. Management of Adult Congenital Heart Disease, 2nd ed. Philadelphia, Elsevier Saunders. 2010. Schwerzmann M, Colman JM. Noncardiac surgery in adult congenital heart disease. Chapter 14, in: Gatzoulis M, Webb GD Daubeney P, eds. Management of Adult Congenital Heart Disease, 2nd ed. Philadelphia, Elsevier Saunders. 2010.

Multimedia Silversides Candice K, Colman Jack M, Kennie A (eds). Heart Disease and Pregnancy. http://www.heartdiseaseandpregnancy.com. Colman JM, Oechslin E, Taylor D. Glossary of Terms in Adult Congenital Heart Disease. http://www.isachd.org/proglossary/ http://www.cachnet.org/achd_index.html.

Department of Medicine Annual Report 2010-2011

36


Jack Colman Silversides CK, Marelli A, Beauchesne L, Dore A, Kiess M, Salehian O, Bradley T, Colman J, Connelly M, Harris L, Khiary P, Mital S, Niwa K, Oechslin E, Poirier N, Schwerzmann M, Taylor D, Vonder Muhll I, Baumgartner H, Benson L, Celermajer D, Greutmann M, Horlick E, Landzberg M, Meijboom F, Mulder B, Warnes C, Webb G, Therrien J. Canadian Cardiovascular Society 2009 Consensus Conference on the Management of Adults with Congenital Heart Disease: Executive Summary. Can J Cardiol. 2010;26(3): 143-150. Silversides CK, Kiess M, Beauchesne L, Bradley T, Connelly M, Niwa K, Mulder B, Webb G, Colman J, Therrien J. Canadian Cardiovascular Society 2009 Consensus Conference on the Management of Adults with Congenital Heart Disease: Outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan syndrome. Can J Cardiol 2010;26(3): e80-e97.

Department of Medicine Annual Report 2010-2011

37


Kenneth Croitoru Gastroenterology External Research Grants Prepared July 2011 Research Area Establishing a complete taxonomic baseline for the human Microbiome Studies on the induction and regulation of colitis in a mouse model Influences of Host Genome on the Human Gut Microbiome: Studies in a Healthy Cohort Carrying Crohn's Disease Risk Alleles Influences of Host Genome on the Human Gut Microbiome: Studies in IBD

Role

Granting Agency

Funding

Period

Co-PI

CIHR Catalyst Group Grant

$100,000

2009 – 2010

PI

Crohn’s Colitis Foundation of Canada

$149,791/yr

2009 - 2012

PI

Canadian Institutes of Health Research; Emerging Team Grant

$491,800

2010-2015

Co-Investigator

Crohn’s and Colitis Foundation of America

$300,000/yr

2010-2013

Department of Medicine Annual Report 2010-2011

38


Allan Detsky General Internal Medicine Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Cavalcanti R, Detsky AS. Publishing history does not correlate with clinical performance among internal medicine residents. Med Educ. 2010 May;44(5):468-74. Scales DC, Riva-Cambrin J, Wells D, Athaide V, Granton JT, Detsky AS. Prophylactic anticoagulation to prevent venous thromboembolism in traumatic intracranial hemorrhage: A decision analysis. Critical Care 2010, 14:R72. Chakrabarti S, Booth CM, Detsky AS, Gold WL. Elements of Confusion. Journal of Hospital Medicine 2010;5(9):560–564. Commentaries Sessions SY, Detsky AS. The “Shadow Government” in Health Care. JAMA. 2010;304(24):27422743. Baerlocher MO, Detsky AS. Discussing Radiation Risks Associated With CT Scans With Patients. JAMA, 2010;304(19):2170-2171. Meltzer DO, Detsky AS. The Real Meaning of Rationing. JAMA, 2010;304(2):2292-2293. Sessions SY, Detsky AS. Incorporating Economic Reality Into Medical Education. JAMA, 2010;304(11):1229-1230. Muller MP, Detsky AS. Public Reporting of Hospital Hand Hygiene Compliance - Helpful or Harmful? JAMA, 2010;304(10):1116-1117. Detsky AS. How to Be a Good Academic Leader. J Gen Intern Med 2010;26(1):88-90. Frackowiak D, Detsky AS. Make Eye Contact and Smile. SGIM Forum 2010;33(7). Sessions SY, Detsky AS. Washington, Ottawa and Health Care Reform: A Tale of 2 Capitals. JAMA 2010;303(20):2078-2079. Tomlinson G, Detsky AS. Composite End Points in Randomized Trials: There Is No Free Lunch. JAMA 2010;303(3):267-268. NON PEERED REVIEW Tomlinson G, Detsky AS. Composite End Points in Clinical Trials Reply. A reply. JAMA, May 5, 2010—Vol 303, No. 17.

Department of Medicine Annual Report 2010-2011

39


Allan Detsky Detsky AS, Alexander GC. Navigating the Shoals of Institutional Politics (and Scandal). SGIM Forum, 2010(April);33(4):5.

Department of Medicine Annual Report 2010-2011

40


Daniel Drucker Endocrinology External Research Grants Prepared July 2011 Research Area

Incretin action and the cardiovascular system GLP-2 receptor activation and the control of cell growth Physiology of GLP-2 Action Elucidating the role of GIP in glucose homeostasis Incretin hormones, diabetes and skeletal health Elucidation of novel mechanisms of glucagon action The role of glucagon-like peptide-1 in cardiac health and disease

Role

Granting Agency

Funding

Period

Co-PI

HSFO NA 6997

$109,100/yr

2010-2013

PI

National Cancer Institute of Canada

$141,000/yr

2006 – 2011

PI

CIHR

$135,368/yr

2006- 2011

PI

CIHR

$111,393/yr

2007 - 2012

Co-PI

CDA

$270,750

2008 - 2011

PI

CIHR

$147,586

2009 - 2014

Co-PI

HSFO

$724,281

2009 - 2014

Department of Medicine Annual Report 2010-2011

41


Daniel Drucker Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., Adeli, K. The glucagonlike peptide-1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice Diabetologia 2010 Mar;53(3):552-61. Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., Drucker D. J. Glucagon-like peptide-1 receptor (GLP1R) signaling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T-cells Diabetologia 2010 Apr;53(4):730-40. Ban, K., Kim, K.-H., Cho, C.-K., SauvĂŠ, S., Diamandis, E. P., Backx, P. H., Drucker, D. J., and Husain, M. GLP-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor Endocrinology 2010 Apr;151(4):1520-31. Sauve, M., Ban, K., Momen, M. A., Zhou, Y-Q., Henkelman, R. M., Husain, M., and Drucker, D. J. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice Diabetes 2010 Apr;59(4):1063-73 Knudsen, L. B., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., Jacobsen, S. D., Moses, A. C., Molck, A. M., Nielsen, H. S., Nowak, J., Solberg, H., Thi, T. D. L., Zdravkovic, M. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 Apr;151(4):1473-86. Buse, J. B., Drucker, D. J., Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., Porter, L. E., and the DURATION 1 Study Group DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks Diabetes Care June;33(6):1255-61 Bahrami, J., Yusta, B., and Drucker, D. J. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel Gastroenterology 2010 Jun;138(7):2447-56. Bahrami, J., Longuet, C., Baggio, L.L., Li, K., and Drucker, D. J. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse Gastroenterology 2010 Sep;139(3):857-868 Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H.and Drucker, D. J. Glucagon-like Peptide-1 Receptor Knockout Mice are Protected from High Fat Diet-Induced Insulin Resistance Independent of Effects on Body Composition Endocrinology 2010 Oct;151(10):4678-87

Department of Medicine Annual Report 2010-2011

42


Daniel Drucker Review Articles Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., and Buse, J. B. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits Diabetes Care 2010 33:428-433 Drucker, D. J., Dritselis, A., Kitkpatrick, P. Liraglutide Nature Reviews Drug Discovery 2010 Apr;9(4):267-8.

Department of Medicine Annual Report 2010-2011

43


Shereen Ezzat Endocrinology External Research Grants Prepared July 2011 Research Area Disease Progression From Carcinoid Tumor to Neuroendocrine Carcinoma Fibroblast Growth Factor Receptor 2 in Normal and Cancer Cells The Regulatory Factor Ikaros in Neuroendocrine Cell Development and Growth

Role

Granting Agency

Funding

Period

PI

The Raymond & Beverly Sackler Foundation

$150,000/yr

2010-2013

PI

CIHR

$140,567/yr

2010-2013

PI

CIHR

$107,346/yr

200-2011

Department of Medicine Annual Report 2010-2011

44


Shereen Ezzat Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Zhu X, Asa SL, Ezzat S. Genetic and Epigenetic Mechanisms Down-regulate FGF Receptor 2 To Induce Melanoma-Associated Antigen-A in Breast Cancer. Am. J. Pathol. 2010;176:2333-43. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, Bamberger AM, Asa SL. Osteopontin (OPN) Expression in Thyroid Carcinoma. Anticancer Res. 2010 5:1681-8. Liu W, Guo M, Ezzat S, Asa SL. Vitamin D Inhibits CEACAM1 To Promote Insulin/IGF-I Receptor Signalling Without Compromising Anti-Proliferative Action. Lab Invest. 2010;91:147-56. A Cassol C, Guo M, Ezzat S, L Asa S. GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules. Endocr Pathol. 2010;21:250-2. Sawka AM, Straus S, Brierley JD, Tsang RW, Rotstein L, Rodin G, Gafni A, Ezzat S, Thabane L, Thorpe KE, Goldstein DP. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer a randomized controlled trial. Trials. 2010 ;11:81. Imran AS, Pelkey M, Clarke DB, Clayton D, Trainer B, Ezzat S. Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty. Int. J. Endocrinol. 2010;pii: 370692. Sawka AM, Ibrahim-Zada I, Galacgac P, Tsang RW, Brierley JD, Ezzat S, Goldstein DP. Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review. Thyroid. 2010;20:1129-38. Sawka A, Straus S, Gafni A, Brierley J, Tsang R, Rotstein L, Ezzat S, Thabane L, Rodin G, Meiyappan S, David D, Goldstein D. How Can We Meet the Information Needs of Patients with Early Stage Papillary Thyroid Cancer Considering Radioactive Iodine Remnant Ablation? Clin Endocrinol (Oxf). 2010 Dec 27. doi: 10.1111/j.1365-2265.2010.03966.x. Zhu X, Asa SL, Ezzat S. Loss of Heterozygosity and DNA Methylation Impose on Germline FGF Receptor 4 Polymorphism to Direct Allelic Selection in Breast Cancer Am. J. Pathol. 2010;177:2860-69.

Department of Medicine Annual Report 2010-2011

45


George Fantus Endocrinology External Research Grants Prepared July 2011 Research Area Role of the enhanced flux through the hexosamine biosynthesis pathway in the pathogenesis of diabetic nephropathy Interactions between cGMP and insulin cell signaling pathways: Physiology and molecular mechanisms of regulation of insulin sensitivity. Vasculoprotective effect of insulin in vivo. Mechanisms of oxidative stress-mediated beta cell glucotoxicity and lipotoxicity in vivo Tyrosine kinase signaling in the pathogenesis of diabetic nephropathy The MiTY Trial (Metformin in Women with Type 2 Diabetes in Pregnancy)

Role

Granting Agency

Funding

Period

PI

CIHR

$106,083/yr

2006 – 2011

PI

CIHR

$121,619/yr

2009 – 2012

Co -Applicant

Heart and Stroke Foundation

$677,230

2008 - 2012

Co - PI

CIHR

$677, 230

2007 - 2012

PI

Canadian Diabetes Association

$74,910

2010-2013

Co-Applicant

CIHR

$321,884/yr

2010-2015

Department of Medicine Annual Report 2010-2011

46


George Fantus Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Can. Res. Treat. 122:647-659, 2010 Shao W., Yu Z., Fantus IG., Jin T. Cyclic AMP signaling stimulates proteasome degradation of Thioredoxin interacting protein (TxNIP) in pancreatic beta-cells. Cell. Signal. 22:1240-1248, 2010. Sison K, Eremina V, Baelde H, Min W. Hirashima M, Fantus IG, Quaggin SE. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J. Am. Soc. Nephrol. 2010. Yu Z, Shao W, Chiang Y, Foltz W, Zhang Z, Ling W, Fantus IG, Jin T. Oltipraz upregulates the nuclear respiratory factor 2 alpha subunit (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia 2010 Dec 16

Department of Medicine Annual Report 2010-2011

47


Denice Feig Endocrinology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

Readiness for Diabetes Prevention in Women with a History of Gestational Diabetes

Co-PI

BBDC

$12,800

2009 – 2011

Exploring Sex Differences in Diabetes Preventative Care in Canada

Co-PI

BBDC Pilot Grant for Innovative Activities Related to Diabetes Education, Management and Care

$10,000

2010-2011

A randomised, parallelgroup, open-label, multinational trial comparing the efficacy and safety of insulin detemir (Levemirďƒ˘) versus human insulin (NPH insulin), used in combination with insulin as part as bolus insulin, in the treatment of pregnant women with type 1 diabetes.

PI

Novo Nordisk Canada Inc.

Undefined

2007 - 2010

Department of Medicine Annual Report 2010-2011

48


Denice Feig Research Area

Role

Granting Agency

Funding

Period

The MiTY Trial (Metformin in Women with Type 2 Diabetes in Pregnancy Trial)

PI

CIHR on SPOR

$100,000

2010-2011

The effect of a low glycemic index (GI) diet on maternal and neonatal markers of glycemic control and post-partum diabetes risk

Co-PI

CDA

$329,724

2010-2013

PI

CDA

$98,081

2010-2011

PI

Educational Grant from Aventis

$10,000

2006-2010

Hypertensive Disorders of Pregnancy and Future Risk of Diabetes in Affected Women and Their Offspring Lantus placental transfer study

Department of Medicine Annual Report 2010-2011

49


Denice Feig Endocrinology Publications for 2010

PEER REVIEWED Al-Shameri A, Hanley A, Tomlinson G, Ni A, Feig DS. Does the Presence of Polycystic Ovary Syndrome Increase the Risk of Obstetrical Complications in Women with Gestational Diabetes? J Mat Fet Neonatal Med 23(6):545-9, 2010 Jun. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care. Jan 33(1):29-33, 2010. Pollex EK, Feig DS, Koren G. Oral hypoglycemic therapy: Understanding the mechanisms of transpacental transfer. J Mat Fet Neonatal Med. 23(3):224-8, 2010. Pollex EK, Moretti M, Koren G, and Feig DS. Safety of insulin glargine use in pregnancy: A systematic review and meta-analysis. Annals of Pharmacotherapy Propylthiouracil-induced agranulocytosis in the third trimester of pregnancy. Murji A, Sobel ML, Feig DS, Sermer M. Obstet Gynecol. Aug 116 Suppl 2:485-7, 2010.

NON PEER REVIEWED Palda VA, Allen L, Bunting P, Mendelssohn D, Clement M, Feig DS, et al (Diabetes Expert Panel),commissioned by the Ontario Ministry of Health and Long-Term Care, Quality Management Program – Laboratory Services. Chronic Disease Prevention & Management Guidelines, Expert Panel Report for July 2010. Feig DS. Oral Hypoglycemic Agents in Pregnancy. Chapter 11, pp 109-116. In: A Practical Manual of Diabetic Pregnancy. Editors: McCance DR, Maresh CM, Sacks DA. Blackwell Publishing 2010.

Department of Medicine Annual Report 2010-2011

50


John Floras Cardiology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

PI

Canadian Institutes of Health Research

$2,000,000

2010-2015

PI

Canadian Institutes of Health Research

$664,735

2007 – 2012

PI

Heart and Stroke Foundation of Ontario

$393,949

2008 – 2011

PI

Heart and Stroke Foundation of Ontario

$217,863

2008 – 2011

Co-Investigator

Heart and Stroke Foundation

$163,788

2008 - 2010

Adaptive servo ventilation for therapy of sleep apnea in heart failure

Co-Investigator

Canadian Institutes of Health Research/SME Collaborative Research Program

$7,449,398

2009 - 2014

The early natural history cardiovascular disease at 4-years postpartum in young women with varying degrees of glucose intolerance in pregnancy

Co-Investigator

Heart and Stroke Foundation of Ontario

Trans-disciplinary team research and training program in sleep and biological rhythms Pathophysiology of sleep apnea in heart and renal failure Neural regulation of the circulation in human heart failure and hypertension Central regulation of autonomic cardiovascular function in human heart failure and sleep apnea Studies of sympathetic nervous system activation in patients with pulmonary arterial hypertension

Department of Medicine Annual Report 2010-2011

$194,558

2009 - 2012

51


John Floras Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Tzemos N, Lyseggen E, Silversides C, Jamorski M, Tong J, Harvey P, Floras J, Siu S (2010). Endothelial function, carotid-femoral stiffness and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta. Journal of the American College of Cardiology 55:660-668. Ryan CM, Floras JS, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson KA, Belenkie I, Pfeifer M, Fleetham J, Hanly PJ, Smilovitch M, Arzt M, Bradley TD for the CANPAP Investigators (2010). Shift in sleep apnea type in heart failure patients in the CANPAP Trial. European Respiratory Journal 35:592-597. Nolan RP, Floras JS, Harvey PJ, Kamath MV, Picton PE, Chessex C, Hiscock N, Powell J, Catt M, Hendrickx H, Talbot D, Chen MH (2010). Behavioral neurocardiac training in hypertension: a randomized controlled trial. Hypertension 55:1033-1039. Spaak J, Tomlinson G, McGowan C, Soleas GJ, Morris BL, Picton P, Notarius CF, Floras JS (2010). Doserelated effects of red wine and alcohol on heart rate variability American Journal of Physiology Heart and Circulatory Physiology 298:H2226-H2231.

NON PEER REVIEWED Bradley TD, Floras JS (2010). (Editors) Sleep apnea: implications in cardiovascular and cerebrovascular disease. 2nd Edition. Volume 231 in: Lung Biology in Health and Disease, Executive Editor, Lenfant, C. New York, Informa Healthcare USA. 396 pages. Yumino D, Floras JS, Bradley TD (2010). Pathophysiological interactions between sleep apnea and heart failure. In: Sleep apnea: implications in cardiovascular and cerebrovascular disease. 2nd Edition. Volume 231 in: Lung Biology in Health and Disease, Executive Editor, Lenfant C. Eds: Bradley TD and Floras JS. New York, Informa Healthcare USA. pp. 302-336.

Department of Medicine Annual Report 2010-2011

52


Shiphra Ginsburg Respirology External Research Grants Prepared July 2011 Research Area The Utility of e-Portfolios for Documentation and Evaluation of the CanMEDS Scholar Role Effects of a Restructured Schedule on Internal Medicine Clinical Teaching Units Investigation of a “ScaleFree” Approach to Evaluating Clinical Performance Professionalism and the Environment: Impact on Behaviour and Quality Improvement Towards contextualized performance assessments: The importance and influence of environmental factors on perceptions of evaluation

Role

Granting Agency

Funding

Period

Senior Investigator

Education Development Fund, Faculty of Medicine

$12,850

2009 – 2011

Senior Investigator

Education Development Fund, Faculty of Medicine

$9,400

2009 – 2010

Co-PI

Medical Council of Canada

$150,000

2007 – 2010

Co-Investigator

American Board of Internal Medicine Foundation

$80,000 US

2008 – 2009

Co-PI

Royal College of Physicians and Surgeons of Canada (The), Medical Education Research Grant

$32,870

2010-2012

Department of Medicine Annual Report 2010-2011

53


Shiphra Ginsburg Respirology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Bryden P, Ginsburg S, Kurabi B, Ahmed N. Professing Professionalism: Are We Our Own Worst Enemy? Faculty’s Experience of Teaching and Evaluating Professionalism in Medical Education. Academic Medicine 2010;85(6):1025-34. Ginsburg S, McIlroy J, Oulanova O, Eva K, Regehr G. Towards Authentic Clinical Evaluation: Pitfalls in the Pursuit of Competencies. Academic Medicine 2010;85(5): 780-786.

NON PEER REVEIEWED Chretien KC, Ginsburg S, Hauer KE. Qualitative Analysis for Medical Educators. Academic Internal Medicine Insight. 8(2) June 2010

Department of Medicine Annual Report 2010-2011

54


Roger Goldstein Respirology External Research Grants Prepared July 2011 Research Area A randomized, activecontrolled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5ųg and 5 ųg Tiotropium inhalation solution delivered by the Respimat® inhaler with Tiotropium inhalation capsules 18 ųg delivered by the Handihaler® Optimizing outcomes gained from pulmonary rehabilitation: the development of a community-based maintenance exercise program for individuals with COPD Upper extremity training in COPD: short and medium term effects on dyspnea, health related quality of life, arm function and arm exercise capacity

Role

Granting Agency

Funding

Period

Co-PI

Boehringer Ingelheim (Canada) Ltd

$25,725

2010-2012

Co-PI

Ontario Lung Association

$46,061

2009 – 2011

PI

Ontario Thoracic Society

$49,494

2008 – 2010

Department of Medicine Annual Report 2010-2011

55


Roger Goldstein Research Area

Role

Granting Agency

Funding

Investigating the relationships between clinical and laboratorybased measures of exercise capacity and measures of physical activity during daily life in subjects with chronic obstructive pulmonary disease (COPD)

PI

Physicians’ Services Incorporated Foundation

$125,031

PI

Ontario Ministry of Health and Long Term Care

$305,000

2005 - 2009

PI

Ontario Thoracic Societ

$49,494

2009-2010

PI

Astra Zeneca Inc.

$59,600

2009-2011

PI

Ontario Ministry of Health and Long-Term Care

$270,000

2007-2010

COPD Pilot Demonstration Project & Chart Abstraction Upper extremity training in COPD: short and medium term effects on dyspnoea, health-related quality of life, arm function and arm exercise capacity Does pulmonary rehabilitation change the self-selected and maximum sustainable walking speed in patients with symptomatic lung disease? Chronic Obstructive Pulmonary Disease (COPD) Demonstration Project

Department of Medicine Annual Report 2010-2011

Period

2007 - 2010

56


Roger Goldstein Research Area The six-minute walk test: responses in healthy Canadians aged 45 – 85 years Non invasive examination of muscle composition in people with chronic obstructive pulmonary disease

Role

Granting Agency

Funding

Co-PI

Ontario Respiratory Care Society

$18,000

Co-Investigator

Department of Medicine Annual Report 2010-2011

Dean’s Fund, Faculty of Medicine, University of Toronto

$25,000

Period 2009-2010

2009-2011

57


Roger Goldstein Respirology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Hill K, Mangovski-Alzamora S, Blouin M, Guyatt G, Heels-Ansdell D, Bragaglia P, Tamari I, Jones K, Goldstein R. Disease-specific education in the primary care setting increases the knowledge of people with chronic obstructive pulmonary disease: A randomized controlled trial. Pat Educ Couns 2010;81(1):14-18. Beauchamp MK, Dolmage TE, Nonoyama M, Goldstein RS, Hill K, Mathur S, Brooks D. Interval versus continuous training in individuals with COPD - a systematic review. Thorax 2010; 65(2): 157-164. Brooks D, Davis L, Vujovic-Zotovic N, Boulias C, Ismail F, Richardson D, Goldstein RS. Sleep-disordered breathing in patients enrolled in an inpatient stroke rehabilitation program. Arch Phys Med Rehabil 2010; 91(4): 659-662. Varadi RG, Goldstein RS. Pulmonary rehabilitation for restrictive lung diseases. Chest 2010; 137(2): 247-248. Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels-Ansdell DM, Erak M, Bragaglia PJ, Tamari IE, Hodder R, Stanbrook MB. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010; 182(7): 673-678. Hill K, Dolmage TE, Woon L, Goldstein R, Brooks D. Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. Thorax 2010; 65(6): 486-491. Marciniuk D, Brooks D, Goldstein RS. The Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease - practical issues: A Canadian Thoracic Society Clinical Practice Guideline. Canadian Respiratory Journal 2010;17(4):159-168. Beauchamp MK, O’Hoski S, Goldstein RS, Brooks D. The effect of pulmonary rehabilitation on balance in individuals with COPD. Archives of Physical Medicine and Rehabilitation 2010;91(9):1460-1465. Beauchamp MK, Brooks D, Goldstein RS. Deficits in postural control in individuals with COPD - emerging evidence for an important secondary impairment. Multidisciplinary Respiratory Medicine. Lacasse Y, Goldstein RS. Prevalence and predictors of nocturnal oxygen desaturation in COPD. (CHEST-09-2937) December 2009. Nici L, Raskin J, Rochester C, Bourbeau J, Carlin B, Casaburi R, Celli B, Cote C, Crouch R, Diaz-Morales L, Donner C, Fahy B, Garvey C, Goldstein R, Lane-Reticker A, Lareau S, Make B, Maltais F, McCormick J, Morgan M, Ries A, Troosters T, ZuWallack R. Pulmonary Rehabilitation. What we know and what we need to know. Journal of Cardiopulmonary Rehabilitation 2009; 29: 141-151.

Department of Medicine Annual Report 2010-2011

58


Roger Goldstein

Goldstein RS, Dolmage TE. Can we increase the exercise training load during pulmonary rehabilitation. Chest 2009; 135: 596-598. Harth L, Stuart J, Montgomery C, Pintier K, Czyzo S, Hill K, Goldstein R, Brooks D. Physical therapy practice patterns in acute exacerbations of chronic obstructive pulmonary disease. Can Resp J 2009; 16(3): 86-92. Moosa D, Blouin M, Hill K, Goldstein RS. Workshops to disseminate the Canadian Thoracic Society guidelines for chronic obstructive pulmonary disease to health care professionals in Ontario: Impact on knowledge, perceived health care practices and participant satisfaction. Can Resp J 2009; 16(3): 1-5. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. Impairments in balance discriminate fallers from non-fallers in COPD. Respiratory Medicine 2009; 103: 1885-1891. Carr SJ, Hill K, Goldstein RS, Brooks, D. Pulmonary rehabilitation after an acute exacerbation of chronic obstructive pulmonary disease in patients who have completed an initial pulmonary rehabilitation program: a pilot study. Journal of Cardiopulmonary Rehabilitation and Prevention 2009; 29: 318-324. Harth, L, Stuart J, Montgomery C, Pintier K, Czyzo S, Hill K, Goldstein R, Brooks, D. Physical therapy practice patterns in acute exacerbations of chronic obstructive pulmonary disease. Canadian Respiratory Journal 2009; 16(3): 86-92. Ferreira I, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional supplementation for chronic obstructive pulmonary disease (Review). The Cochrane Database of Systematic Reviews, Issue 4; 2009. DOI: 10.1002/14651858.CD000998.pub2. Janaudis-Ferreira T, Hill K, Goldstein R, Wadell K, Brooks D. Arm exercise training in patients with chronic obstructive pulmonary disease: a systematic review. J Cardiopulm Rehabil Prev 2009; 29(5): 277-283. Varadi RG, Goldstein R. Pulmonary rehabilitation and pharmacotherapy. Semin Respir Crit Care Med 2009; 30(6): 636-48. Goldstein RS, Dolmage TE. Can we increase the exercise training load during pulmonary rehabilitation? Chest 2009; 135: 596-598. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. Impairments in balance discriminate fallers from non-fallers in COPD. Respiratory Medicine 2009;103(12):1885-1891.

Department of Medicine Annual Report 2010-2011

59


Pamela J. Goodwin Hematology/Oncology External Research Grants Prepared July 2011 Research Area Survivorship in a long-term breast cancer cohort: Integration of the biologic, psychosocial, lifestyle and healthrelated quality of life factors Prognosis in BRCA1 associated breast cancer Lifestyle intervention study in adjuvant treatment of early breast cancer Vitamin D in breast cancer Vitamin D as a predictor of breast cancer risk and tamoxifen benefit in NSABP-P1

Role

Granting Agency

Funding

Period

PI

Breast Cancer Research Foundation

$934,326 US

2004-2011

PI

National Institutes of Health

$1,294,964 US

2005-2011

PI

Novartis Pharmaceuticals Canada, Inc.

$5,100,000

2007-2012

PI

Breast Cancer Research Foundation

$250,000

2008-2011

PI

Canadian Cancer Society Research Institute

$269,378

2009-2011

Department of Medicine Annual Report 2010-2011

60


Pamela J. Goodwin Research Area A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (NCIC MA.32) Ontario Familial Registry for studies in breast cancer risk Predictors of local recurrence in ductal carcinoma in situ: A population-based outcomes analysis A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer

Role

Granting Agency

Funding

Period

PI

NIH/NCI/CTEP

$7,164,000

2010-2016

Co-I

National Institutes of Health (U.S.)

$11,944,096

1995-2011

Co-I

Canadian Breast Cancer Research Alliance

$1,274.373

2007-2012

Co-I

Breast Cancer Research Foundation

$40,061

2010-2011

Department of Medicine Annual Report 2010-2011

61


Pamela Goodwin Hematology/Oncology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a Tumor Promoting Effects of High-Fat Diet Independent of Insulin Resistance in HER2/Neu Mammary Carcinogenesis. Breast Cancer Research and Treatment 2010; 122:647-659 Keegan THM, Milne RL, Andrulis IL, Chang ET, Sangaramoothy M, Phillips KA, Giles GG, Goodwin PJ, Apicella C, Hopper JL, Whittemore AS, John EM. Past Recreational Physical Activity, Body Size, and AllCause Mortality Following Breast Cancer Diagnosis: Results from the Breast Cancer Family Registry. Breast Cancer Research and Treatment 2010; 123:531-542 Goodwin PJ, Pritchard K. Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. Journal of Clinical Oncology 2010; 28:3405-3407 Bordeleau LJ, Pritchard KI, Loprinzi C, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ. A Multicenter Randomized Crossover Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology 2010; 28:5147-5152 Muraca L, Leung D, Clark A, Beduz MA, Goodwin PJ. Breast cancer survivors: Taking Charge of Lifestyle Choices After Treatment. European Journal of Oncology Nursing 2010; Jan 21 (Epub ahead of print) doi:10.1016/j.ejon.2009.12.001 DeCensi A, Puntoni M, Goodwin PJ, Cazzaniga M, Gennari A, Bonami B, Gandini S. Metformin and Cancer Risk – A Meta-Analysis. Cancer Prevention Research 2010; 3:1451-1461 Goodwin PJ, Meyerhardt J, Hursting SD. Host Factors and Cancer Outcomes. Journal of Clinical Oncology 2010; 28:4019-4021 Goodwin PJ. Metabolic Syndrome, Insulin Resistance and Inflammation in Breast Cancer: Impact on Prognosis and Adjuvant Interventions. Current Breast Cancer Reports 2010; 2:182-189

Review Articles Bordeleau L, Panchal S, Goodwin PJ. Prognosis of BRCA Related Breast Cancer: A Summary of Evidence. Breast Cancer Research and Treatment 2010; 119:13-24

Commentaries Goodwin PJ. Commentary on Protani M, Coory M, Martin JH. Effect of Obesity on Survival in Women with Breast Cancer: Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment 2010; 123:637

Department of Medicine Annual Report 2010-2011

62


Allan Gordon Neurology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

Community Alliances in Health Research and Knowledge Exchange (CAHR)

Co-PI

CIHR

$500,000/yr ($70,000/yr to Wasser Pain Management Center)

2007 – 2012

Neuropathic Pain Database. A multicentre observational database

Co-PI

Pfizer (Investigator Driven)

$250,000 per year, $35,000 going to Dr. Gordon

Headache and Sexual Pain Disorders (at Woman’s College Hospital Headache Clinic)

PI

Merck Investigator Driven

$25,000

2010-2011

Tar gin in chronic pain

Co-PI

Purdue Pharma

$25,000

2010-2012

Needs Assessment of Women with Sexual Pain Disorders

PI

Eli Lilly Investigator driven

$50,000

2010-2012

Research Partnership in Pain and Addiction

PI

Purdue Pharma

$375,000

2009-2011

Department of Medicine Annual Report 2010-2011

2008-2011

63


Allan Gordon Research Area Grant to fund an academic preceptorship program and promote and electronic communication system The Rasch Foundation Fifth Pillar Program in Self Management at the Wasser Pain Management Centre

Role

Granting Agency

Funding

Period

PI

Pfizer

$125,000

2011-2012

Director

Rasch Foundation

$300,000

2010-2012

Department of Medicine Annual Report 2010-2011

64


Allan Gordon Neurology Publications for 2010 NON-PEER REVEIEWED Original Research and Systematic Reviews Nijjar S.S., Gordon A., Clark M.: Entry demographics of migraine patients referred to a tertiary care pain clinic. Cephalalgia E Pub June 2009. 2010 30(1):87-91 2010 Choiniere M, Dion D, Peng P, Banner R, Barton PM, Boulanger A, Clark AJ, Gordon AS et al. The Canadian STOP-PAIN project- Part 1: Who are the patients on the waitlists of multidisciplinary pain treatment facilities? Can J Anaesth. 2010 57:539-48 Guerriere DN, Choiniere M. Dion D, Peng P, Stafford-Coyte E, Zagorski B, Banner T, Barton PM, Boulanger A, Clark AJ, Gordon AS et al: The Canadian STOP-PAIN project- Part 2: what is the cost of pain for patients on waitlists of multidisciplinary pain treatment facilities? Can J. Anaesth 2010 57:549-58 Gordon A, Rashiq S, Moulin D, Clark A, Beaulieu A, Eisenhoffer J, Piraino P, Quigley P, Harsanyi Z, Darke A: Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010 15:169-78 Gordon A, Callahan D, Cloutier C, Spink D, Dzongowski P et al. Buprenorphine transdermal system inadults with chronic low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clinical Therapeutics 2010 32:844-859 Nijjar S.S., Pink L., Gordon A.: Examination of migraine management in emergency departments. Accepted for publication in Pain Research and Management. In 2011 Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. Botulinum toxin injections for low-back pain and sciatica. Cochrane Database of Systematic Reviews 2011, Issue 1. t

Department of Medicine Annual Report 2010-2011

65


Gordon Greenberg Gastroenterology External Research Grants Prepared July 2011 Research Area Genetic, Serological, and Microbial Factors Related to Patterns of Ileal inflammation A Cross Sectional Study to Determine the Relationship between Serum Infliximab Concentration and Efficacy in Patients with Luminal Crohn’s Disease

Role

Granting Agency

Funding

Period

Co-Applicant

Crohn’s and Colitis Foundation of Canada

$450,000

2008 – 2011

Co-PI

Schering Plough

$980,000

2006 - 2011

Department of Medicine Annual Report 2010-2011

66


Gordon Greenberg Gastroenterology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 59: 49-54, 2010.

Department of Medicine Annual Report 2010-2011

67


Edward Keystone Rheumatology External Research Grants Prepared July 2011 Research Area Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease- Modifying Antirheumatic Drug (DMARD) Therapy in Biological-Na誰ve Subjects with Rheumatoid Arthritis (Part 1), followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2) PO6129 A Two-Stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension (Protocol No. AC-052-510)

Role

Granting Agency

Funding

Period

PI

Schering Canada Inc.

$60,000

2010-Ongoing

PI

Actelion Pharmaceuticals

$40,000

2009-Ongoing

Department of Medicine Annual Report 2010-2011

68


Edward Keystone Research Area

Role

Granting Agency

Funding

Period

A Phase III, Multi-Center, Randomized, DoubleBlind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Combination with Methotrexate vs. Methotrexate Alone In Subjects with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate.

PI

Bristol-Myers Squib

$60,000

2002 – 2010

Rare Diseases Clinical research Network. VCRC Longitudinal Protocol # 5502, 5503, 5504, 5505, 5506, 5510, 5515

Sub-PI

NIH

$100,000

2009-Ongoing

A Phase IIIB Multi-Center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naïve Early Erosive RA Subjects Treated with Abatacept Plus Methotrexate Compared with Methotrexate

PI

Bristol-Myers Squib

$33,821

2005 –2010

Department of Medicine Annual Report 2010-2011

69


Edward Keystone Research Area A Multi-Center Continuation Study of the Human anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients with Rheumatoid Arthritis (DE019) A Prospective MultiCentre, Randomised, Double-Blind Active Comparator Controlled Parallel Groups Study Comparing the Fully Human Monoclonal AntiTNF Antibody D2E7 Given every Second Week with Methotrexate Given Weekly and the Combination of D2E7 and Methotrexate Administered over 2 Years in Patients with Early Rheumatoid Arthritis A Multi-Center Randomized Double-Blind Placebo-Controlled Study of the Human anti-TNF Monoclonal Antibody D2E7 in Rheumatoid Arthritis Currently Receiving Treatment with Methotrexate (DE020)

Role

Granting Agency

Funding

Period

PI

Abbott Laboratories

$72,000

2001 – Open

PI

Abbott Laboratories

$22,000

2001 – Open

PI

Abbott Laboratories

Department of Medicine Annual Report 2010-2011

$47,000

2001 – Open

70


Edward Keystone Research Area Health economic evaluation in conjunction with clinical trial DE013, a prospective multi-center randomized, double-blind, active comparatorcontrolled, parallelgroups trial comparing the fully human monoclonal anti TNF antibody D2E7 given every second week with methotrexate given weekly and the combination of D2E7 and methotrexate administered over 2 years in patients with early rheumatoid arthritis A Phase III Multicenter Study of the Safety and Efficacy of Human AntiTNF Monoclonal Antibody Adalimumab in Subjects with Active Ankylosing Spondylitis. A randomized, placebocontrolled, double-blind, multicenter study to evaluate the safety and Efficacy of rituximab in combination with methotrexate in patients with active rheumatoid Arthritis who have had an inadequate response to anti-TNF therapies.

Role

Granting Agency

Funding

Period

PI

Abbott Laboratories

$12,000

2002 – Open

PI

Abbot Laboratories

$30,000

2005 – Open

PI

Hoffman La Roche

$65,000

2002 – Open

Department of Medicine Annual Report 2010-2011

71


Edward Keystone Research Area

Role

Granting Agency

Funding

Period

Long-term extension study of safety during treatment with ocrelizumab (MRA) in patients completing treatment in MRA core studies.

PI

Hoffman La Roche

$56,690

2006 – Open

Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu’s Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4Ig) in Large Vessel Vasculitis (AGATA) (Protocol No. 5523)

Sub-PI

NIH

$76,000

2009-Ongoing

A Randomised, DoubleBlind, International Study To Evaluate The Efficacy And Safety Of Various Retreatment Regimens Of Rituximab In Combination With Methotrexate In RA Patients With An Inadequate Response To Methotrexate.

PI

Hoffman La Roche

$36,597

2005 – Open

Department of Medicine Annual Report 2010-2011

72


Edward Keystone Research Area A randomized, doubleblind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis with an inadequate response to anti-TNF-α therapy A Phase 2, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC10004 in Subjects with Active Psoriatic Arthritis A Multicenter, Randomized, Doubleblind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Role

Granting Agency

Funding

Period

PI

Hoffman La Roche

$13,500

2007 – Open

PI

Celgene Corporation

$8,288

2006 – 2009

PI

Centocor, Inc.

$41,770

2005 – Open

Department of Medicine Annual Report 2010-2011

73


Edward Keystone Research Area A Multicenter International Observational Study of the Long-term Safety of Infliximab A Multicenter, Randomized, Doubleblind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNFα Agent(s) Multi-Site Clinical and Reproducibility Protocol for the Rheumatoid Arthritis Assays Comparison of active therapies in patients with active disease despite methotrexate therapy A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects who Switch from Intravenous to Subcutaneous Abatacept Therapy

Role

Granting Agency

Funding

Period

PI

Centocor

$20,000

2002 – Open

PI

Centocor, Inc.

$39,921

2006 – Open

PI

Umedik Inc

$61,080

2007 – Open

PI

CIHR/VA

$14,000,000

2007 – Open

PI

Bristol-Myers Squibb

$12,256

2008 - Open

Department of Medicine Annual Report 2010-2011

74


Edward Keystone Research Area A Phase IIIb, Multicenter Study with a 12- week Double-blind, placebocontrolled, Randomized Period followed by an Open-label, Extension Phase to Evaluate the Safety and Efficacy of Cerolizumab Pegol Administered to Patients with Active Rheumatoid Arthritis A Phase II, Multi-Center, Randomized, DoubleBlind, Methotrexate Controlled Study to Assess The Clinical Efficacy, Safety, and Tolerability of CH-1504 in Patients With Active Rheumatoid Arthritis A Phase IIIb Open-Label Run-In And Double-Blind Randomized Study to Evaluate the Safety and Efficacy of Centolizumab Pegol Administered Concomitantly With Stable-Dose Methotrexate in Patients With Active Rheumatoid Arthritis

Role

Granting Agency

Funding

Period

PI

UCB

$58,400

2009 – Open

PI

Chelsea

$57,160

2007 – Open

PI

UCB

$62,848

2007 – Open

Department of Medicine Annual Report 2010-2011

75


Edward Keystone Research Area Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy Biomarkers as a prognostic tool in RA Biomarkers in RA An Open-Label Randomized Trail of Etanercept and Methotrexate Vs. Etanercept Alone in the Treatment of Rheumatoid Arthritis

Role

Granting Agency

Funding

Period

PI

Roche

$37,600

2009 - Open

PI

Roche

$46,400

2009 - Open

PI

Crescendo Bioscience

$49,000

2008 - Open

PI

Crescendo Bioscience

$200,000

2008 - Open

PI

Amgen

$22,000

2009 - Open

Department of Medicine Annual Report 2010-2011

76


Edward Keystone Research Area Effectivness of TNF inhibitors switching Global Multicenter Observational Study in Rheumatoid Arthritis Patients who are NonResponders or Intolerant to a Single Tumor Necrosis Factor (TNF)- Inhibitor Canadian Early Arthritis Cohort (CATCH) – A Prospective Cohort Study of Adults with New-Onset Inflammatory Arthritis Symptoms Studied By The Network of Early Arthritis Researcher (NEAR)

Role

Granting Agency

Funding

Period

PI

Schering Plough

$ 20,000

2009 - Open

PI

Roche

$15,500

2009 - Open

PI

Amgen

$100,000

2004-Ongoing

Department of Medicine Annual Report 2010-2011

77


Edward Keystone Rheumatology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Is a 12-Week Trial Sufficient to Evaluate Clinical Responses to Etanercept or Methotrexate Treatment in Early Rheumatoid Arthritis? Arthur Kavanaugh, Edward Clark Keystone, JingYuan Feng, and MIchele Hooper. Rheumatology, Letter to the Editor, February 24, 2010, p 1-2. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Keystone E, Genovese M, Klareskog L, Hsia E, Hall S, Miranda P. Pazdur J, Bae, S0C, Palmer W. Xu S, and Rahman M. Ann Rheum Dis 2010; Vol 69, 1129-1135 Disease activity, physical function and radiographic progression after long-term therapy with adalimumab plus MTX: 5 year results of premier. van der Heijde D, Breedveld F, Kavanaugh A, Keystone E, Landewe, R, Patra K, Pangan A. Accepted Journal of Rheumatology June 2010 20100208.R1. J Rheumatol. 2010 Nov;37(11):2237-46. Epub 2010 Oct 1. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The Go-Forward Study. Keystone EC, Genovese M, Klareskog L, Hsia E, Hall S, Mirand P, Pzdur J, Bae S-C, Palmer W. Zrubek J, Wiekowski M, Visvanathan S, Wu Z and Rahman M. Ann Rheum Dis. 2009, 68, 789-796. ACR Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis Despite Methotrexate: Data From the RAPID 1 and 2 Trials. R. F. van Vollenhoven, D. Felson, V. Strand, M.E. Weinblatt, K. Luijtens, and E. C. Keystone. Arthritis Care & Research, Volume 63, Issue 1, pages 128–134, January 2011 Paul Emery, Roy Fleischmann, Désirée van der Heijde, Edward C. Keystone, Mark C. Genovese, Philip G. Conaghan, Elizabeth C. Hsia, Weichun Xu, Anna Baratelle, Anna Beutler, and Mahboob U. Rahman. The effect of Golimumab on radiographic progression in rheumatoid arthritis: results of the Go-Before and Go-Forward randomized controlled Studies. Accepted for publication Arthritis & Rheum Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, Cravets M, Shaw T, and Hagerty D. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methorexate. Ann Rheum Dis 2010 June 69 (6):1158-61 Epub 2010 May 3. Keystone E, Kavanaugh A, Weinblatt M, Kaushik P, and Pangan A. Clinical consequences of delayed addition of adalimumab to Methotexate Therapy over 5 years in patients with rheumatoid arthritis. Manuscript # 2010-0752.R1 Journal of Rheumatology 2011. DOI: 10.3800/jrheum.100752 Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better long-term outcomes: post-hoc analysis of a randomized controlled trial. Keystone E, Curtis J, Fleischmann R, Mease P, Khana D, Smolen J Furst D, Coteur G and Combe B. Accepted for Publication J Rheumatol Dec 2010. Manuscript ID 2010-0935.R1

Department of Medicine Annual Report 2010-2011

78


Edward Keystone

Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Research & Therapy, 2010 Nov 17;12(6):R211. Factors associated with radiographic progression in rheumatoid arthritis patients treated with methotrexate. J Rheumatol 2011;38: (in press Feb 2011). Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW. J Rheumatol. 2010 Nov 15. Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries. Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, McCroskery P, Baumgartner SW, Markenson JAJ Rheumatol. 2011 Jan;38(1):21-8. A randomised, placebo-controlled, Phase IIb, multicentre study to evaluate the efficacy of the P2X7 antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Edward C Keystone, Iain B McInnes, Millie M Wang, Mark Layton, Sally Hollis. Accepted for publication Annals of Rheum Diseases 2011 as Extended Report. Treating rheumatoid arthritis to target: recommendations of an international task force. Josef Smolen, Daniel Aletaha1, Johannes W J Bijlsma, Ferdinand C Breedveld, Dimitrios Boumpas, Gerd Burmester, Bernard Combe, Maurizio Cutolo, Maarten de Wit, Maxime Dougados, Paul Emery, Alan Gibofsky, Juan Jesus Gomez-Reino, Boulos Haraoui1, Joachim Kalden, Edward C Keystone, Tore K Kvien, Iain McInnes, Emilio Martin-Mola, Carlomaurizio Montecucco, Monika Schoels, Desirée van der Heijde. Ann Rheum Dis 2010April; 69 (4) 631-7 Eub 2010 Mar 9. American College of Rheumatology/European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials. David T. Felson, Josef S. Smolen, George Wells, Bin Zhang, Lilian H. D. van Tuyl, Julia Funovits, Daniel Aletaha, Renée Allaart, Joan Bathon, Stefano Bombardieri, Peter Brooks, Andrew Brown, Matucci Cerinic, Hyon Choi, Bernard Combe, Maarten de Wit, Maxime Dougados1 Paul Emery, Dan Furst, Juan Gomez-Reino, Gillian Hawker , Edward Keystone, Dinesh Khanna, John Kirwan Tore Kvien, Robert Landewé, Joachim Listing, Kaleb Michaud, Emilio Martin Mola, Pam Montie, Ted Pincus, Pam Richards, Jeff Siegel, Lee Simon29, Tuulikki Sokka, Vibeke Strand, Peter Tugwell Alan Tyndall, Desirée van der Heijde, Suzan Verstappen, Barbara White, Fred Wolfe, Angela Zink, and Maarten Boers. Accepted for publication, Arthritis & Rheum (In Press 2010) Contact: Maarten Boers. Indirect comparisons of the efficacy of biologic anti-rheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional DMARDs or to an anti-TNF agent: A metaanalysis. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y Bombardier C, and Keystone E. Diseases Ann Rheum Dis, Vol 70, Issue 2, February 2011 pp 266-271.

Department of Medicine Annual Report 2010-2011

79


Edward Keystone

NON-PEER REVIEWED Systematic Reviews Treating Rheumatoid Arthritis to Target: Recommendations of an Internal Task Force. Josef S Smolen, Daniel Aletaha, Johannes WJ Bijlsma, Dimitrios T Boumpas, Ferry C Breedveld, Gerd Burmester, Bernard Combe, Maxime Dougados, Paul Emery, Alan Gibofsky, Maurizio Cutolo, Tore Kvien, Carlomaurizio Montecucco, Edward Keystone, Paul Haroui, Emilio Martin-Mola, Martinus de Wit, Monika Schoels, Desirée van der Heijde, Joachim Kalden, Iain McInnes, and Juan Gomez-Reino Accepted Annals of Rheumatic Diseases January 2010

Review Articles Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009. Furst DE, Keystone E, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dorner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, singer N, Van Riel PL, Weinblatt ME, Weisman MH, and Winthrop K. Ann rheum Dis. 2010 Jan; 69 Suppl 1: i2-29. Can Tumor Necrosis Factor Inhibitors Be Safely Used in Pregnancy? YM Ali, B Kuriya, C Orozco, JJ Cush and E Keystone. J Rheumatol 2010, Jan; 37(1):9-17. Epub 2009 Dec 15. Review Edward C. Keystone. Biologics: Rapid Control of Symptoms in Rheumatoid arthritis. In: Biologics and Beyond: Understanding and Meeting The Needs of People With Rheumatoid Arthritis. Review. London: BMJ Group 2010: 2-5. Edward Keystone. Does Anti-TNF-α Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Long-term Data". Review Accepted for Publication, J of Rheumatology 2011. MS No. 2010-0995.

Department of Medicine Annual Report 2010-2011

80


Stephen Lapinsky Respirology External Research Grants Prepared July 2011 Research Area A Randomized Controlled Trial of Continuous Venovenous Hemofiltration versus Continuous Venovenous Hemodialysis in Critically Ill Patients with Acute Kidney Injury: A Pilot Study Collaborative H1N1 Influenza Adjuvant Treatment (CHAT) Pilot Trial NSERC Strategic Network: Healthcare support through information technology enhancements Improving outcomes from renal replacement therapy (RRT) in acute kidney injury (AKI): multihospital pilot prospective cohort study

Role

Granting Agency

Funding

Period

Co-Investigator / Site PI

University of Toronto Division of Nephrology

Unknown

2007 – 2010

Site Investigator

CIHR/PSI

$300,000

2009-2011

Collaborator

NSERC

$5,000,000

2008 - 2013

PI

MSH/ UHN AFP Innovation Funds

$66,331

2008 – 2010

Department of Medicine Annual Report 2010-2011

81


Stephen Lapinsky Respirology Publications for 2010 PEER REVEIEWED Journal Articles Lapinsky SE, Hallett D, Collop N, Drover J, Lavercombe P, Leeman M, Moola S, Paruk F, Bernstein M, Moodley J. Evaluation of standard and modified severity of illness scores in the obstetric patient. J Crit Care. 2010 Nov 22 Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med. 2010;38:1773-1785. Fieghen HE, Friedrich JO, Burns KE, Nisenbaum R, Adhikari NK, Hladunewich MA, Lapinsky SE, Richardson RM, Wald R, Acute Kidney Injury Research Group FT. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol. 2010;11:32. Nin N, Lombardi R, Frutos-Vivar F, Esteban A, Lorente JA, Ferguson ND, Hurtado J, Apezteguia C, Brochard L, Schortgen F, Raymondos K, Tomicic V, Soto L, González M, Nightingale P, Abroug F, Pelosi P, Arabi Y, Moreno R, Anzueto A; VENTILA Group. Early and small changes in serum creatinine concentrations are associated with mortality in mechanically ventilated patients. Shock. 2010;34:109-16. Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, Henry B, Lapinsky S, Loeb M, McDonald LC, Ofner M, Paton S, Reynolds D, Scales D, Shen S, Simor A, Stewart T, Vearncombe M, Zoutman D, Green K. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010 May 19;5(5):e10717. Kuster SP, Drews S, Green K, Blair J, Davis I, Downey J, Fowler R, Katz K, Lapinsky S, McRitchie D, Pataki J, Powis J, Rose D, Sarabia A, Simone C, Simor A, Stewart T, McGeer A. Epidemiology of influenza-associated hospitalization in adults, Toronto, 2007/8. Eur J Clin Microbiol Infect Dis. 2010 Apr 29. T. Oluyomi-Obi, L. Avery, A. C. Schneider, Kumar, S. Lapinsky, S. Menticoglou, R. Zarychanzki. Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A. J Obstet Gynaecol Can 2010;32:443–447. Fowler RA, Webb SA, Rowan KM, Sprung CL, Thompson BT, Randolph AG, Jouvet P, Lapinsky S, Rubinson L, Rello J, Cobb JP, Rice TW, Uyeki T, Marshall JC. Early observational research and registries during the 2009 influenza A pandemic. Crit Care Med. 38(3 Suppl), 2010. Epidemic viral pneumonia. Curr Opin Infect Dis. 23:139-44, 2010. Lapinsky SE. H1N1 Novel Influenza A in Pregnant and Immunocompromised patients. Crit Care Med. 2010; 38[Suppl.]:e52– e57.

Editorials Lapinsky SE. Critical illness as a result of influenza A/H1N1 infection in pregnancy. BMJ 2010;340:c1235

Department of Medicine Annual Report 2010-2011

82


Gary Lewis Endocrinology External Research Grants Prepared July 2011 Research Area Canada Research Chair in Diabetes Heart and Stroke Foundation of Canada Career Investigator Award Determining the mechanisms of hepatic and intestinal lipoprotein overproduction in insulin resistance Mechanism of fatty acidinduced impairment of glucose-stimulated insulin secretion The role of c-reactive protein (CRP) in modulating insulin action and secretion Exenatide regulation of intestinal and hepatic lipoprotein particle production in humans

Role

Granting Agency

Funding

Period

PI

CRC

$100,000/yr

2006 – 2010

PI

Heart and Stroke Foundation of Canada

86,325/yr

2007 – 2010

PI

CIHR

$120,606/yr

2007 – 2012

PI

CDA

$90,000/yr

2007 - 2010

PI

HSFO

$85,946/yr

2008-2010

PI

Eli Lily Canada

$293,034

2009 - 2011

Department of Medicine Annual Report 2010-2011

83


Gary Lewis Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. Insulin acutely inhibits intestinal lipoprotein secretion in humans, in part by suppressing plasma free fatty acids. Diabetes 59:580-587, 2010. Carpentier AC, Bourbonnais A, Frisch F, Giacca A, Lewis GF. Plasma non-esterified fatty acid tolerance and hyperglycemia are associated with lipid-induced impairment of beta cell function in humans. J. Clin. Endocrinol. Metab. Mar;95(3):1256-64, 2010. Epub 2010 Jan 22. Jenkins DJA, Chiavaroli L, Wong JMW, Kendall C, Lewis GF, Vidgen E, Connelly PW, Leiter LA, Josse RG, Lamarche B. The effect of adding monounsaturated fat to a dietary portfolio of cholesterollowering foods in hypercholesterolemia. Can Medical Association Journal Nov 8. 2010 Xiao C, Pavlic M, Szeto L, Patterson B, Lewis GF. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein metabolism in humans. Diabetes Oct 27, 2010. Xi L, Xiao C, Szeto L, Naples M, Adeli K, Lewis GF. C-reactive protein impairs hepatic insulin sensitivity and insulin signalling in rats: role of mitogen activated protein kinases. Hepatology Sep 24, 2010. Giacca A, Oprescu A, Xiao C, Carpentier A, Lewis GF. Lipid-induced pancreatic beta cell dysfunction: Focus on in vivo studies. Am J Physiol, Endocrinol and Metab. 2010 Nov 30 Bandsma R, Lewis GF. Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia. Atherosclerosis Sep;212(1):40-1, 2010.

Department of Medicine Annual Report 2010-2011

84


Conrad Liles Infectious Diseases External Research Grants Prepared July 2011

Research Area

Role

Canada Research Chair (Tier 1) in Inflammation and Infections Diseases Award

PI

Liles Research Funds

Co-PI

Angiopoietins and Vascular Protection: Therapeutic Implications Emerging Infections

Granting Agency Canada Foundation for Innovation (CFI)/Canada Institute for Health Research (CIHR) McLaughlin Centre for Molecular Medicine

Funding

Period

$1,400,000

2006 – 2013

$150,000

2008 - 2012

Co-PI

CIHR

$835,000

2010 - 2015

Co-PI

CIHR TEAM Grant Canadian Foundation for Innovation (CFI)

$4,500,000

2006 – 2011

$4,000,000

2006 – 2011

Emerging Infections

Co-PI

Biomarkers for Severe Malaria

Co-Investigator

DARPA,USA

$670,000

2010-2012

Inhaled NO for Fandemic Influenza

Co-Investigator

DARPA,USA

$630,000

2010-2012

Department of Medicine Annual Report 2010-2011

85


Conrad Liles Infectious Diseases Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Boggild, AK, Buckner FS, Nicks B, Van Voorhis WC, McMullen R, Liles WC. Delusional parasitosis: retrospective analysis of 23 consecutive cases presenting to an academic medical center over a six year period. Int J Infect Dis 2010; 14:e317-e321. PMID: 19683952. Morris AM, Stewart TE, Shandling M, McIntaggart S, Liles WC. Establishing an antimicrobial stewardship program. Healthcare Q 2010; 13:64-70. Wang F, Yang H, Lu Z, Hawkes M, Kain KC, Liles WC. Fas(CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages; J Inflamm 2010; 7:30 Finney CAM, Lu Z, Hawkes M, Yeh W-C, Liles WC, Kain KC. Divergent roles of IRAK-4-mediated innate immune responses in two experimental models of severe malaria. Am J Trop Med Hyg 2010; 83:69-74. Hawkes M, Li, X, Crockett M, Diassiti A, Liles WC, Liu J, Kain KC. Malaria exacerbates experimental mycobacterial infection in vitro and in vivo. Microbes Infect 2010; 12:864-874. Hawkes M, Li X, Crockett M, Diassiti A, Liles WC, Liu J, Kain KC. CD36 deficiency confers relative resistance to mycobacterial infection. BMC Infect Dis 2010; 10:299. Mei SHJ, Haitsma, JJ, dos Santos CC, Deng Y, Lai PFH, Slutsky AS, Stewart DJ*, Liles WC*. Mesenchymal stromal cells reduce inflammation while enhancing bacterial clearance and improving sepsis. Am J Resp Crit Care Med 2010; 182:1047-1057. *Co-Senior Authors. Chun CD, Liles WC, Frevert CW, Glenny RW, Altemeier WA. Mechanical ventilation modulates Toll-like receptor-induced inflammation via a MyD88-dependent, TLR4-independent pathway. BMC Pulm Med 2010; 10:57. Morris AM, Liles WC, Stewart TE. Antimicrobial stewardship in the design of critical care. Int J Intensive Care 2010; Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 2011; 52:e14-e17. Ricciuto DR, dos Santos CC, Hawkes M, Totl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, FoxRobichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles WC. Angiopoietin-1 and -2 are predictive biomarkers of morbidity and mortality in a longitudinal cohort of patients with severe sepsis. Crit

Care Med 2011 Jan 14.

Department of Medicine Annual Report 2010-2011

86


Conrad Liles Manuscripts Tsunooka N, Hirayama S, Medin JA, Liles WC, Keshavjee S, Waddell TK. A tissue-engineered solution for the post-pnemonectomy space: a novel approach. Ann Thoracic Surg 2011; Minnema BJ, Bridge S, Liles WC. Case report: a snake in the grass. J Gen Intern Med 2011; in press. Darwish I, Mubareka S, Liles WC. Immunomodulatory approaches for the treatment of influenza. Exp Rev Anti-Infect Ther 2011; in press Higgins S, Kain KC, Liles WC. Immunomodulatory adjunctive therapeutic approaches to improve clinical outcome in severe malaria. Exp Rev Anti-Infect Ther 2011; Lee W, Liles WC. Endothelial activation in severe infections. Curr Opin Hematol 2011; Kim H, Higgins S, Liles WC, Kain KC. Endothelial activation and dysregulation in malaria: a potential target for novel therapeutics. Curr Opin Hematol 2011 Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, Rajwans N, Wolofsky KT, Streiner DL, Liles WC, Cserti-Gazdewich CM, Kain KC. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS One 2011; Page AV, Liles WC. Colony-stimulating factors in prevention and management of infectious diseases. Infect Dis Clin North Am, 2011, Conroy AL, McDonald CR, Silver KL, Liles WC, Kain KC. Complement activation: a critical mediator of adverse fetal outcomes in malaria in pregnancy? Trends Parasitol 2011; Page AV, Kotb M, Low DR, McGeer A, Kain KC, Liles WC. Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome; Clin Infect Dis 2011; Finney CAM, Musoke C, Dhabangi A, Oravecz T, Dzik WH, Cserti-Gazdewich CM, Liles WC, Kain KC. Shingosine-1-phosphate levels are decreased in African children with cerebral malaria and SIP receptor agonists confer protection in experimental cerebral malaria. Mol Med 2011;.

NON PEER REVIEWED Page AV, Liles WC. Immunomodulators. In: Principles and Practices of Infectious Diseases, 7th edition. Mandell GL, Bennett JE, Dolin R (eds), Elsevier Churchill Livingstone, Philadelphia, PA, 2010, p.611624.

Department of Medicine Annual Report 2010-2011

87


Kenneth Locke General Internal Medicine External Research Grants Prepared July 2011

Research Area

Role

Granting Agency

Funding

Period

E-Portfolios for documentation and evaluation of the Scholar Role in Postgraduate Training

Co-PI

Department of Medicine and Educational Development Fund

$12,850

2009 - 2011

PI

UHN/MSH Academic Medical Organization and Ontario Ministry of Health, Phase III Innovation Fund

$185,543

2009 – 2011

IT Platform for improved communication in the hospital ward setting

Department of Medicine Annual Report 2010-2011

88


Kenneth Locke General Internal Medicine Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Karani R, Chheda S, Dunn K, Locke K, Bates C. Update in Medical Education. J Gen Intern Med.

Department of Medicine Annual Report 2010-2011

89


Alexander Logan Nephrology External Research Grants Prepared July 2011 Research Area Self-monitoring of blood pressure in primary care in older diabetic patients with uncontrolled systolic hypertension Role of extracellular fluid volume in inducing obstructive sleep apnea in refractory hypertension Role: Principal investigator The CHIPS trial (control of hypertension in pregnancy study) Disturbed sleep and drug resistant hypertension Adaptive servo ventilation for therapy of sleep apnea in heart failure Managing gestational diabetes mellitus in the wireless age: a RCT of glucose telemonitoring A clinical phenotyping and computational facility for the study of complex diseases

Role

Granting Agency

Funding

Period

PI

Heart and Stroke Foundation of Ontario

$629,619

2006 – 2010

PI

Heart and Stroke Foundation of Ontario

$104,801

2008 – 2010

Co-Investigator, Member of Steering Committee

CIHR

$3,743,575

2008 – 2014

PI

Heart and Stroke Foundation of Ontario

$119,458

2010-2012

Co-PI

CIHR

$7,449,398

2009 – 2014

PI

Ontario Ministry of Health and Long-term Care

$164,010

2009 - 2010

Co-PI

Canadian Foundation for Innovation

$1,575,000

2010-2012

Department of Medicine Annual Report 2010-2011

90


Alexander Logan Nephrology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Friedman O, Bradley TD, Ruttanaumpawan P, Logan AG. Independent association of drug resistant hypertension to reduced sleep duration and efficiency. Am J Hypertens 2010; 23(2):174-179. Ryan CM, Floras JS, Logan AG, Kimoff J, Series F, Morrison D, Ferguson KA, Belenkie I, Pfeifer M, Fleetham J, Hanly PJ, Smilovitch M, Arzt M, Bradley TD for the CANPAP Investigators. Shift of sleep apnea type in heart failure patients in the CANPAP trial. Eur Respir J 2010; 35(3):592-597. Friedman O, Bradley D, Chan CC, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010; 56(6):1077-1082.

Review Articles Logan AG, Bradley TD. Sleep apnea and cardiovascular disease. Curr Hypertens Rep 2010; 12(3):182188.

Editorials Logan AG. Ambulatory blood pressure monitoring; its time to move on! J Hypertens 2010; 28:20002001.

Book Chapters Friedman O, Logan AG. Treatment of hypertension in sleep apnea. In: Bradley TD, Floras JS, eds. Sleep Apnea Implications in Cardiovascular and Cerebrovascular Disease, Second Edition. Vol 231, Chap 11, New York: Informa Healthcare USA, Inc. 2010, pp 180-191.

Department of Medicine Annual Report 2010-2011

91


Angela Mailis Gagnon Phys Med External Research Grants Prepared July 2011 Research Area Pharmacoepidemiology of chronic non cancer pain patients; Opioids and cognition; Characteristics and functional status of patients entering a comprehensive pain clinic. Systematic review: Prevalence of neuropathic pain; Effects of sodium pentobarbital in patients with chronic pain; Prevalence and characteristics of non dermatomal somatosensory abnormalities in chronic pain patients Development/dissemination of an educational tool for appropriate opioid prescribing for family physicians

Role

Granting Agency

Funding

Period

CPI

AFP/ MOHLTC

$650,000

2006 - 2011

PI

Pfizer Canada

PI

Industry Concortium

Department of Medicine Annual Report 2010-2011

$65,000

$50,000

2009 - 2010

2010-2010

92


Angela Mailis Gagnon Phys Med Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Mailis-Gagnon A, Nicholson K, Chaparro L. Analysis of complaints to a tertiary care pain clinic over a nine-year period Pain Res Manage 2010, Volume 15 Issue 1: 17- 23.

Review Articles Mailis-Gagnon A, Nicholson K. Non Dermatomal Somatosensory Deficits (NDSDs): Overview of unexplainable negative sensory phenomena in chronic pain patients. Review. Curr Opin Anesthesiol 2010;23:593-597.

Department of Medicine Annual Report 2010-2011

93


Susanna Mak Cardiology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

PI

Heart and Stroke Foundation of Ontario, Grant in Aid, NA 6372

$172,788

2008-2011

PI

Heart and Stroke Foundation of Ontario

$191,291

2008 – 2011

Unknown

Unknown

Heart and Stroke Foundation of Canada, Personnel Support Program

$250,000

2009 – 2010

Skeletal Muscle Dysfunction in Idiopathic Pulmonary Arterial Hypertension

Co-Investigator

Ontario Thoracic Society

$34,408

2008 – 2010

Studies of Sympathetic Nervous System Activation in Patients with Pulmonary Arterial Hypertension Sex Determinants in Left Ventricular and Mechanical Performance in Patients with and without Heart Failure

Department of Medicine Annual Report 2010-2011

94


Susanna Mak Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD. Nocturnal Rostral Fluid Shift: A unifying concept for the pathogenesis of obstructive and central sleep apnea in mean with heart failure. Circulation 2010; 121:1598-1605. Mitoff PR, Gam D, Ivanov J, Al-hesayen A, Azevedo EF, Newton GE, Parker JD, Mak S. Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart 2010.

NON PEERED REVIEWED Wainstein R, Sasson Z, Mak S. Sexual dimorphism in sex determinants of left ventricular mechanical performance: a human in vivo study. 2010, submitted for peer review. Van Spall H, Atzema C, Mak S, Newton G, Chong A, Stukel T, Lee D. Utility of an empirical initial triage risk assessment in acute heart failure: Illustration using the Canadian Triage Acuity Scale. 2010, submitted for peer review.

Department of Medicine Annual Report 2010-2011

95


Sangeeta Mehta Respirology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

A randomized trial of daily sedative interruption in critically ill, mechanically ventilated patients being managed with a sedation protocol

PI

CIHR

$510,697

2009

Towards RECOVER -Longterm outcomes and needs assessment in survivors of prolonged mechanical ventilation and their caregivers

Co-Investigator

Alternate Funding Plan/ Ministry of Health/ Province of Ontario

$185,000

2009 – 2011

Towards RECOVER -Longterm outcomes and needs assessment in survivors of prolonged mechanical ventilation and their caregivers

Co-Investigators

CIHR

$754,357

2009 – 2011

OSCILLation for ARDS Treated Early (OSCILLATE) Trial

Co-Investigator

CIHR

$691,537

2009

Department of Medicine Annual Report 2010-2011

96


Sangeeta Mehta Research Area PE METRICS: Pulmonary Embolism: Methodology, Epidemiology & Treatment In Critical care Study Canadian Survey of Nurses’ Assessment and Management of Pain in the Critically Ill SLEAP- Sleep, Cognition and Psychology (SLEAPSCP): Psychological, cognitive and sleep morbidity following the use of a sedation protocol vs a sedation protocol and daily sedative interruption in critically ill, mechanically ventilated adults EPITEC - Epidemiology of ThromboEmbolism in Critical care SLEAP-PS: Psychological morbidity associated with two sedation strategies in the critically-ill. SLEAP: A randomized trial of daily sedative interruption in critically ill, mechanically ventilated patients being managed with a sedation protocol

Role

Granting Agency

Funding

Period

Co-Investigators

Physicians’ Services Incorporated

$41,600

2009 - 2010

Co-Investigator

American Association of Critical Care Nurses Large Critical Care Grant

$15,000

2009-2010

Co-PI

CIHR

$63,494

2010-2012

Co-Investigator

CIHR

$63,889

2010-2011

PI

Canadian Intensive Care Foundation

$25,000

2010-2011

CIHR

$999,832

2007-2012

PI

Department of Medicine Annual Report 2010-2011

97


Sangeeta Mehta Respirology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Crowther MA, Cook DJ, Albert M, Williamson D, Meade MO, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE, For the Canadian Critical Care Trials Group. The 4Ts scoring system for heparin induced thrombocytopenia in medical-surgical ICU patients. J of Crit Care 2010 Feb 9 Mehta S, Heffer MJ, Maham N, Nelson DL, Klinger JR, Levy MM. Impact of endotracheal tube size on preextubation respiratory variables. J Crit Care. 2010 Sep;25(3):483-8. Gordon AC, Russell JA, Walley KR, Singer J, Ayers A, Storms MM, Holmes CL, HĂŠbert PC, Cooper J, Mehta S, Granton JT, Cook DJC, Presneill JJ, for the Vasopressin and Septic Shock Trial (VASST) Investigators. The effects of vasopressin on acute renal dysfunction in septic shock. Intensive Care Med 2010; 36 (1): 83. Foster R, Suri A, Filate W, Hallett DC, Meyer J, Ruijs T, Callum J, Sutton D, Mehta S. Use of Intravenous Immune Globulin (IVIG) in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med. 2010 Dec;20(6):403-8. Ethier C, Burry L, Martinez-Motta C, Tirgari S, Jiang D, McDonald E, Granton J, Cook D, Mehta S, for the Canadian Critical Care Trials Group. Recall of ICU Stay in patients managed with a Sedation Protocol or a Sedation Protocol with Daily Sedative Interruption: A Pilot Study. J of Crit Care 2010 Oct 1

NON PEER REVIEWED Fanelli V, Mehta S. Open the lung with high-frequency oscillation ventilation or conventional mechanical ventilation? It may not matter! Critical Care 2010; 14:.

Department of Medicine Annual Report 2010-2011

98


Chantal Morel Hematology/ Oncology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

A Double-Blind, Randomized, PlaceboControlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients with Fabry Disease and AT1001Responsive GLA Mutations

Sub-Investigator

Industry-Sponsored

$102,900

2010 - 2011

Department of Medicine Annual Report 2010-2011

99


Chantal Morel Hematology/ Oncology Publications for 2010 PEER REVIEWED Journal Articles Saechao C., Valles-Ayoub, Y., Esfandiarifard S., Haghighatgoo A., No D., Shook S., Mendell J.R., Rosales-Quintero X., Felice K.J., Morel C.F., Pietruska M., Darvish D. Novel GNE mutations in hereditary inclusion body myopathy patients of non-Middle Eastern descent. Genet Test Mol Biomarkers 14:157-162. Goh ES, Li C, Horsburgh S, Kasai Y, Kolomietz E, Morel CF. The Roberts syndrome/SC phocomelia spectrum--a case report of an adult with review of the literature. Am J Med Genet A 152A:472-8. Published. (Trainee Publication) Shlien A, Baskin B, Achatz MI, Stavropoulos DJ, Nichols KE, Hudgins L, Morel CF, Adam MP, Zhukova N, Rotin L, Novokmet A, Druker H, Shago M, Ray PN, Hainaut P, Malkin D. A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes. Am J Hum Genet. 2010 Nov 12;87(5):631-42. Moreno-De-Luca D; SGENE Consortium, Mulle JG; Simons Simplex Collection Genetics Consortium, Kaminsky EB, Sanders SJ; GeneSTAR, Myers SM, Adam MP, Pakula AT, Eisenhauer NJ, Uhas K, Weik L, Guy L, Care ME, Morel CF, Boni C, Salbert BA, Chandrareddy A, Demmer LA, Chow EW, Surti U, Aradhya S, Pickering DL, Golden DM, Sanger WG, Aston E, Brothman AR, Gliem TJ, Thorland EC, Ackley T, Iyer R, Huang S, Barber JC, Crolla JA, Warren ST, Martin CL, Ledbetter DH. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet. 2010 Nov 12;87(5):618-30.

Department of Medicine Annual Report 2010-2011

100


Andrew Morris Infectious Diseases External Research Grants Prepared July 2011 Research Area Antimicrobial stewardship

Role

Granting Agency

Funding

Period

Co-PI

University of Toronto – Department of Medicine

$60,000

2009 - 2011

Department of Medicine Annual Report 2010-2011

101


Andrew Morris Infectious Diseases Publications for 2010 PEER REVIEWED Reviews P. George, A.M. Morris. Pro/con debate: Should antimicrobial stewardship programs be adopted universally in the intensive care unit?. Critical Care 2010; 14:205-10. doi 10.1186/cc8219 A.M. Morris, T.E. Stewart, M. Shandling, S. McIn taggart, W.C. Liles. Establishing an antimicrobial stewardship program. Healthcare Quarterly. 2010; 13:64-70.

Department of Medicine Annual Report 2010-2011

102


Gary Newton Cardiology External Research Grants Prepared July 2011 Research Area Investigations of diet in heart failure

Role

Granting Agency

Funding

Period

PI

Canadian Institutes of Health Research

$100,000

2009 - 2010

Department of Medicine Annual Report 2010-2011

103


Gary Newton Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Mitoff PR, Gam D, Ivanov J, Al-Hesayen A, Azevedo ER, Newton GE, Parker JD, Mak S. Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart. 2010 Sep 28. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J. 2010 Aug;160(2):264-271.e1. Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation. 2010;121:1598-605.

Department of Medicine Annual Report 2010-2011

104


Geoffrey Nguyen Gastroenterology External Research Grants Prepared July 2011 Research Area Prevalence of venous asymptomatic venous thromboembolism in hospitalize IBD patients and strategies for their early detection Predictors and Effectiveness of Prompt Cholecystectomy Following Admission for Acute Gallstone Pancreatitis Characterization of Racial Disparities in Inflammatory Bowel Disease Among African Americans The effect of outdoor air pollution on the incidence and prognosis of the inflammatory bowel diseases in Canada Durability of HBV DNA Suppression in Cirrhotics After Stopping Therapy Identifying IBD Susceptibility Genes

Role

Granting Agency

Funding

Period

PI

Canadian Institutes of Health Research

$90,000

2009 – 2011

PI

University of Toronto Dean’s fund

$10,000

2009 – 2014

PI

Foundation for Digestive Health and Nutrition

$225,000

2007 – 2010

Co-Investigator

Canadian Institutes of Health Research

$224,874

2008 – 2010

Co-Investigator

NIH/NIDDK

$1,255,106

2008 – 2013

Co-Investigator

NIDDK/ NIH

$1,246,250

2007 – 2012

Department of Medicine Annual Report 2010-2011

105


Geoffrey Nguyen Research Area Racial Disparities in the Quality of Care in the Management of Inflammatory Bowel Disease in the Medicaid Population Postoperative Outcomes Following Colectomy in Elderly Ulcerative Colitis Patients The effect of outdoor air pollution on the development of the inflammatory bowel diseases Co-Supervisor. Optimising the Phenotypic Classification of Paediatric Inflammatory Bowel Disease. CAG/CIHR. PI: Sherlock, Mary

Role

Granting Agency

Funding

Period

PI

Procter and Gamble

$15,000

2007 - 2009

Co-Investigator

MSI Foundation

$47,868

2008 – 2010

Co-Investigator

Canadian Association of Gastroenterology

$84,600

2008 – 2010

PI

CAG/CIHR

$120,000

2009-2011

Department of Medicine Annual Report 2010-2011

106


Geoffrey Nguyen Gastroenterology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Yanai H., Nguyen GC, Yun L, Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Paul Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S. The Practice of Gastroenterologists in Treating Flaring IBD Patients with C. difficile: Antibiotics Alone or Combined Antibiotics/Immunomodulators? Inflamm Bowel Dis. EPub 2010 Nov 18. Nguyen GC, Leung W, Weizman AV. Increased Risk of Vancomycin-resistant Enterococcus (VRE) Infection Among Patients Hospitalized for Inflammatory Bowel Disease in the United States. Inflamm Bowel Dis. EPub 2010 Nov 8. Nguyen GC. Dinani A, Pivovarov K. Endoscopic Management and Outcomes of Pregnant Women Hospitalized for Nonvariceal Upper GI Bleeding: A Nationwide Analysis. Gastrointest Endosc. 2010 Nov;72(5):954-9. EPub 2010 Sep 25. Kaplan GG, Hubbard J, Panaccione R, Shaheen AM, Quan H, Seow C, Nguyen GC, Crespin M, Ghosh S, Myers RP. The Risk of Comorbidities on Postoperative Outcomes in Inflammatory Bowel Disease Patients. Arch Surg. Wu H and Nguyen GC. Association of liver cirrhosis with venous thromboembolism among hospitalized patients: a nationwide U.S. study. Clin Gastroenterol Hepatol. EPub 2010 May 23. Nguyen GC, LaVeist TA, Harris ML, Wang MH, Datta LW, Brant SR. Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol. EPub 2010 May 18. Anand N, Chong CA, Chong RY, Nguyen GC. Impact of diabetes on postoperative outcomes following colon cancer surgery. J Gen Intern Med. EPub 2010 Mar 30.

Review Articles Weizman AV and Nguyen GC. Diverticular Disease: Epidemiology and Management. Can J Gastroenterol.

NON PEER REVIEWED Commentaries Nguyen GC and Yeo EL. Prophylaxis of venous thromboembolism in IBD. Lancet. 2010 Feb 20; 375(9715): 616-7. Epub 2010 Feb 8. Published

Review Articles Weizman AV and Nguyen GC. Colon cancer screening in 2010: an up-date. Minerva Gastroenterol Dietol. 2010 Jun;56(2):181-8. Published

Department of Medicine Annual Report 2010-2011

107


Mirek Otremba General Internal Medicine External Research Grants Prepared July 2011

Research Area

Role

Granting Agency

Funding

Period

Medical informatics – electronic clinical documentation

Co-PI

AHSC AFP INNOVATION FUND

$200,000

2008 - 2010

Department of Medicine Annual Report 2010-2011

108


John Parker Cardiology External Research Grants Prepared July 2011 Research Area Pharmacological Preconditioning: Observations Concerning the Organic Nitrates Development of a New Technique to Assess Endothelial Function: Flow Mediated Constriction Studies of sympathetic nervous system activation in patients with pulmonary hypertension

Role

Granting Agency

Funding

Period

PI

CIHR

$320,000

2006 – 2010

PI

HSFO

$496,000

2008 – 2013

Co-I

HSFO

$173,000

2008 - 2011

Department of Medicine Annual Report 2010-2011

109


John Parker Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Gori T, Grotti S, Dragoni S, Lisi M, Sonnati S, Di Stolfo G, Fineschi M, Di Stolfo G, Parker JD. Vascular Function Assessment: Flow-mediated constriction complements the information of flow-mediated dilation. Heart 2010 Jan; 96:141-7 Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Thomas GR, Oelze M, Daiber A, Parker JD. Tolerance to nitroglycerin-induced preconditioning of the endothelium: A human in-vivo study. Am J Physiol Heart Circ Physiol 2010; 298(2):H340-5 Liuni A, Luna M, Uxa A, Gori T, Parker JD. Rosuvastatin prevents endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2 dependent mechanism. J Am Coll Card 2010; 55:1002-6 DiFabio JM, Thomas GR, Parker JD. The impact of low dose folic acid on nitroglycerin induced endothelial dysfunction. Can J Cardiol. 2010; 26:461-5 Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, Sermer M, Colman JM, SilversidesCK. Btype natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010; 56:247-53 Liuni A, Luca MC, Melling M, Lisi M, Dragoni S, Di Stolfo G, Gori T, Parker JD. Observations of timebased measures of flow-mediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function Am J Physiol Heart Circ Physiol. 2010; 299:H939-45 Luca MC, Liuni A, DiFabio J, Gori T, Parker JD. Neither captopril nor amiloride prevent endothelial dysfunction induced by ischemia and reperfusion in the human forearm vasculature. Can J Physiol Pharmacol. 2010; 88:996-1001 Liuni A, Luca MC, Di Stolfo G, Uxa A, Mariani J, Gori T, Parker JD. Atorvastatin coadministration prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in humans in vivo. J Am Coll Card 2010; 57:93-8 Uxa A, Thomas GR, Gori T, Parker JD. Standard Versus Low Dose Transdermal Nitroglycerin: Differential Effects on the Development of Tolerance and Abnormalities of Endothelial Function. J Cardiovasc Pharmacol. 2010; 56:354-9. Miner SES, Al-Hesayen A, Nield LE, Gori T, Parker JD. Acetylcholine acutely induces NOS dysfunction in the human coronary circulation. Exp Physiol 2010; 95:1167-76 Mitoff PR, Gam D, Ivanov J, Al-Hesayen A, Azevedo ER, Newton GE, Parker JD, Mak S. Cardiac-specific sympathetic activation in men and women with and without heart failure. Heart 2011; 97:382-7.

Department of Medicine Annual Report 2010-2011

110


John Parker Yumino D, Wang H, Floras JS, Newton GN, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Relation of Periodic Leg Movements During Sleep and Mortality in Patients With Systolic Heart Failure. Am J Cardiol 2011;107:447–451 Finimundi HC, Parker JD, Caramori P. Effects of amiloride therapy on exercise capacity and myocardial perfusion in chronic stable angina: A randomized crossover study. J Card Pharm Chow BDW, Freeman MR, Levin L, Hopkins RB, Provost Y, Bowen JM, Tarride, Dennie C, Cohen E, Marcuzzi D, Iwanochko R, Moody AR, Paul N, Parker JD, O’Reilly D, Xie F, Goeree R, and/for the OMCAS Investigators. Ontario Multi-detector Computed Tomographic Coronary Angiography Study (OMCAS): A Field Evaluation of Diagnostic Accuracy. Arch Int Med 2011 Perampaladas K, Parker JD, Gori T. The impact of rosiglitazone on nitric oxide bioavailability and endothelial function. . Clin Hemorheol Microcir. 2010; 45:325-8 Liuni A, Luca MC, Gori T, Parker JD. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury. Clin Hemorheol Microcirc 2010; 45:161-7

Case Reports Mariani JA, McDonald MA, Nanthakumar K, Parker JD, Ross HJ. Cardiac resynchronization therapy after atrioventricular node ablation for rapid atrial fibrillation in a heart transplant recipient with late allograft dysfunction. J Heart Lung Transplant 2010; 29:704-6.

Department of Medicine Annual Report 2010-2011

111


Ravi Retnakaran Endocrinology External Research Grants Prepared July 2011 Research Area Longitudinal Associations of Adipocytokines and Markers of Sub-Clinical Inflammation with changes in insulin resistance and beta-cell function in Women with a History of Gestational Diabetes Mellitus Role of the Arginine / Nitric Oxide Metabolome in the Early Natural History of Cardiovascular Disease in Young Women The Role of Erythropoietin in Promoting b-Cell Survival and Function The Impact of Maternal Abnormalities in Pregnancy on Breast Milk Composition and Subsequent Infant Metabolic Development The Impact of Dietary Factors on the Pathophysiology of Gestational Diabetes and Subsequent Type 2 Diabetes

Role

Granting Agency

Funding

Period

PI

CIHR

$744,845

2007 – 2012

Co-PI

Canadian Diabetes Association

$275,000

2010 - 2013

Co-PI

CIHR Physicians’ Services Incorporated Foundation

$157,000

2008 - 2010

Co-Investigator

Canadian Foundation for Diabetic Research

$14,996

2009 – 2011

PI

Canadian Diabetes Association

$272,590

2008 - 2011

Department of Medicine Annual Report 2010-2011

112


Ravi Retnakaran Research Area The Impact of Maternal Abnormalities in Pregnancy on Breast Milk Composition and Subsequent Infant Metabolic Development The Impact of Maternal Diet in Pregnancy on Risk of Gestational Diabetes Progression of Core and Emerging Components of the Metabolic Syndrome: a Longitudinal Analysis Insulin Resistance and Beta Cell Dysfunction in Early Childhood: The Role of Maternal and Infant Metabolic Risk Factors The Early Natural History of Cardiovascular Disease at 4-years Postpartum in Young Women with Varying Degrees of Glucose Intolerance in Pregnancy Undefined

Role

Granting Agency

Funding

Period

Co-Investigator

Canadian Diabetes Association

$225,388

2009 - 2012

PI

Connaught New Staff Matching Grant

$30,000

2008 - 2010

Co-Investigator

Canadian Diabetes Association

$284,949

2008 - 2011

Co-Investigator

CIHR

$440,000

2008 - 2013

PI

Heart and Stroke Foundation of Ontario

$194,000

2009 - 2012

Co-PI

CIHR India-Canada Collaborative Teams in Childhood Obesity Research

$486,295

2010-2015

Department of Medicine Annual Report 2010-2011

113


Ravi Retnakaran Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 2010; 33(8):1798-1804. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta-cell dysfunction and fasting glycaemia Diabetologia 2010; 53:268-276. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of LDL cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2010; 95:4345-53. Retnakaran R, Qi Y, Sermer M, Connelly PW, Zinman B, Hanley AJ. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women Journal of Clinical Endocrinology and Metabolism 2010; 95:670-7. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral anti-diabetic medications: a pilot study with sitagliptin. Diabetes, Obesity and Metabolism 2010; 12:909-915. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes, Obesity and Metabolism 2010; 12:65-71. Retnakaran R, Qi Y, Sermer M, Connelly PW, Zinman B, Hanley AJ. Gestational diabetes and postpartum physical activity: evidence of lifestyle change one year after delivery. Obesity 2010; 18(7):1323-9. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Risk of early progression to prediabetes or diabetes in women with recent gestational dysglycemia but normal glucose tolerance at 3months postpartum. Clinical Endocrinology 2010; 73(4):476-483. Hamilton JK, Odrobina E, Hanley AJ, Zinman B, Retnakaran R. Effect of maternal insulin sensitivity during pregnancy on infant weight gain and adiposity. Obesity 2010; 18:340-346. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran R, Raboud J, Qi Y, Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus: (CANOE trial): A double-blind randomized controlled study. Lancet 2010; 376(9735):103-11.

Department of Medicine Annual Report 2010-2011

114


Ravi Retnakaran Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, Retnakaran R, Woo M. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010; 207(13):2831-2842. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, Harris SB, Zinman B, Hanley AJ. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010; 33(6):1379-1381. Ley SH, Hegele RA, Connelly PW, Harris SB, Mamakeesick M, Cao H, Gittelsohn J, Retnakaran R, Zinman B, Hanley AJ. Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. Cardiovascular Diabetology 2010 Aug 18;9:39. Ley SH, O'Connor DL, Retnakaran R, Hamilton JK, Sermer M, Zinman B, Hanley AJ. Impact of maternal metabolic abnormalities in pregnancy on human milk and subsequent infant metabolic development: methodology and design. BMC Public Health 2010 Oct 6;10:590.

Other Retnakaran R. Inflammation, Adipokines and Gestational Diabetes Mellitus. In: Gestational Diabetes During and After Pregnancy. Eds. Kim C, Ferrara A. Springer-Verlag New York, Page 139-153, 2010 Retnakaran R, Zinman B. Treatment of Type 1 Diabetes Mellitus in Adults. In: Endocrinology. LJ DeGroot and JL Jamieson (eds) 6th Ed. Elsevier Saunders. Philadelphia PA. Vol 1, Pages 840-857, 2010

Department of Medicine Annual Report 2010-2011

115


Cheryl Rosen Dermatology External Research Grants Prepared July 2011 Research Area The risk of developing arthritis in patients with psoriasis A Phase 3 Multicenter, Randomized, Doubleblind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis and previously treated with Biologic Anti-TNFα Agents. Interplay Between Skin and Joint Disease Genetics Factors in Psoriasis and Psoriatic Arthritis A Phase 3 Multicenter, Randomized, Doubleblind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis

Role

Granting Agency

Funding

Period

Co-PI

Canadian Institutes of Health Research

499,557/yr

2007 – 2012

PI

Centocor Inc.

$10,980/patient

2010

PI

CIHR, Musuloskeletal Health, Arthristis, Skin and Oral Health Priority

$100,000

2009 – 2010

PI

Centocor Inc.

$15,533/patient

2010

Department of Medicine Annual Report 2010-2011

116


Zion Sasson Cardiology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Banks L, Sasson Z, Busato M, Goodman, J. Impaired left and right ventricular function following prolonged exercise in young athletes: Influence of exercise intensity and responses to Dobutamine stress. Journal of Applied Physiology – 108 (1):112-9, 2010.

Department of Medicine Annual Report 2010-2011

117


Mark Silverberg Gastroenterology External Research Grants Prepared July 2011 Research Area Genetic, Serological and Microbial Factors Related to Patterns of Ileal Inflammation Identification of Susceptibility Genes and Genotype-Phenotype Studies in IBD Interdisciplinary Team Grant on Etiology of Inflammatory Bowel Disease: Gene, Microbe and Environment Interactions The Role of ATG16L1 in Crohn’s disease Comparing rheumatoid arthritis and inflammatory bowel disease by serology, gene studies and ethnicity: using commonalities and differences to develop etiologic hypotheses Immune Regulation and Biomarker Development in Pediatric and Adult Onset Autoimmune Diseases

Role

Granting Agency

Funding

Period

PI

Crohn’s and Colitis Foundation of Canada

$450,000

2008 – 2011

PI

National Institutes of Health/ NIDDK

$1,025,000

2007 – 2012

Co-Investigator

Alberta Heritage Foundation for Medical Research

$5,000,000

2009 – 2014

Co-Investigator

Crohn’s and Colitis Foundation of Canada

$450,000

2008 – 2011

Co-Investigator

CIHR

$969,315

2007 – 2010

Co-Investigator

CIHR

$1,318,689

2007 - 2011

Department of Medicine Annual Report 2010-2011

118


Mark Silverberg Research Area Influences of Host Genome on the Human Gut Microbiome: Studies in a Healthy Cohort Carrying Crohn’s Disease Risk Alleles . Genetic Markers of Outcomes in Crohn’s Disease

Role

Granting Agency

Funding

Period

Co-Investigator

Canadian Institutes of Health Research (CIHR), Emerging Team Grant: Canadian Microbiome Initiative

$2,465,100

2010-2015

PI

. Crohn’s and Colitis Foundation of Canada (CCFC), Priority Partnership Program

$920,000

2010-2013

Department of Medicine Annual Report 2010-2011

119


Mark Silverberg Gastroenterology Publications for 2010 PEER REVEIEWED Journal Articles Seow CH, Newman A, Irwin S, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: A predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 2010; 59(1): 49-54. Turner D, Kolho KL, Mack DR, Raivio T, Leleiko N, Crandall W, Markowitz J, Silverberg MS, Jänne OA, Stempak J, Hyams J, Griffiths AM. Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis. Inflammatory Bowel Diseases 2010; 16(3): 469-73. Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart AH, Silverberg MS, Hyams J, Guyatt GH. Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflammatory Bowel Diseases 2010; 16(4):651-6. Wang K, Baldassano R, Zhang H, Qu HQ, Imielinski M, Kugathasan S, Annese V, Dubinsky M, Rotter JI, Russell RK, Bradfield JP, Sleiman PM, Glessner JT, Walters T, Hou C, Kim C, Frackelton EC, Garris M, Doran J, Romano C, Catassi C, Van Limbergen J, Guthery S, Denson L, Piccoli D, Silverberg M, Stanley CA, Monos D, Wilson DC, Griffiths A, Grant SF, Satsangi J, Polychronakos C, Hakonarson H. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Human Molecular Genetics 2010; 19(10):2059-67. Turner D, Mack D, Leleiko N, Walters TD, Uusoue K, Leach ST, Day AS, Crandall W, Silverberg M, Markowitz J, Otley AR, Keljo D, Mamula P, Kugathasan S, Hyams J, Griffiths AM. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138(7):2282-91. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D’Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; The NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics 2010; 42(4): 332-7 McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D’Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; The NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoli. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nature Genetics 2010; 42(4): 332-7.

Department of Medicine Annual Report 2010-2011

120


Mark Silverberg Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, Crandall W, Markowitz J, Otley AR, Xu W, Hu P, Griffiths AM, Silverberg MS. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS ONE 2010; 5(9): e13085. doi:10.1371/journal.pone.0013085. Franke A, McGovern DP, Barrett JC, ... Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D’Amato M, , Weersma RK, Kugathasan S, Griffiths AM, Silverberg MS, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nature Genetics 2010; 42(12):1118-25.

NON PEER REVEIEWED Book Chapters Silverberg MS. Genetics of inflammatory bowel disease. In: Bernstein CN, ed. The Inflammatory Bowel Disease Yearbook- Volume 6. London: Remedica Publishing, 2010: 1-20. Published

Department of Medicine Annual Report 2010-2011

121


Katherine Siminovitch Rheumatology External Research Grants Prepared July 2011 Research Area This proposal is directed at delineating the roles of phosphatases in regulating lymphocyte development and function. This proposal is directed at the characterization of susceptibility genes/molecules for rheumatoid arthritis This proposal is directed at the roles of actinregulatory proteins in lymphocyte signaling This grant is aimed at identifying the susceptibility variants underlying primary biliary cirrhosis This proposal is directed at disease genomics: reduction to practice This proposal is directed at disease gene mapping to clinical practice (a provincial program in clinical genomics)

Role

Granting Agency

Funding

Period

PI

CIHR

$148,214/yr

2005 – 2010

PI

CIHR

$174,0404/yr

2009 - 2014

PI

CIHR

$171,000/yr

2006 - 2011

Co-PI

CIHR

$285,474/yr

2008 -2011

Co-PI

Canadian Foundation for Innovation

$1,920,000/yr

2006 - 2012

Co–PI

Ontario Research Fund

$964,200/yr

2006 - 2012

Department of Medicine Annual Report 2010-2011

122


Katherine Siminovitch Research Area This NET grant is aimed at defining the molecular determinants of risk and outcome in inflammatory arthritis. This proposal is aimed at characterizing the susceptibility genes/molecules for inflammatory bowel disease. A new murine model for preclinical studies in prostate cancer Immunology and genetics

Role

Granting Agency

Funding

Period

PI

CIHR

$400,000/yr

2007 – 2012

PI

Crohn’s & Colitis Foundation of Canada

$150,000/yr

2007 - 2010

PI

Ontario Institute for Cancer Research

$144,000/yr

2009 – 2012

Canada Research Chair

Canadian Foundation for Innovation

$190,000/yr

2006 - 2011

Department of Medicine Annual Report 2010-2011

123


Katherine Siminovitch Rheumatology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews CL Galligan, KA Siminovitch, EC Keystone, V Bykerk, OD Perez and EN Fish. Fibrocyte activation in rheumatoid arthritis. Rheumatology 49(4):640-51, 2010. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53(4):730-40, 2010. Kushwah R, Wu J, Oliver JR, Jiang G, Zhang J, Siminovitch KA, Hu J. Uptake of apoptotic DC converts immature DC into tolerogenic DC, which induce differentiation of Foxp3+ regulatory T cells. European Journal of Immunology 40(4):1022-35, 2010. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FAS, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, BIRAC Consortium, Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJH, Costenbader KH, Criswell LA, Crusius JBA, Cui J, de Bakker PIW, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TWJ, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TRDJ, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AHM, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PLCM, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P, YEARConsortium, Wijmenga C, Karlson EW, Toes REM, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics 42(6):508-14, 2010. Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics 42(8):655-7, 2010. Liu X, Invernizzi P, Lu E, Kosoy R, Lu Y, Bianchi I, Podda M, Xu C, Xie G, Macciardi F, Selmi, C Lupoli S, Atkinson EJ, Shigeta R, Ransom M, Lleo A, Lee AT, Mason AL, Myers RP, Peltekian KM, Ghent CN, Bernuzzi F, Zuin M, ICPBCG, Gregersen PK, Heathcote EJ, Hirschfield GM, Siminovitch KA, Amos CI, Gershwin ME, Seldin MF. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics 42(8):658-60, 2010. Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, Liu X, Heathcote EJ, Hirschfield GM, Siminovitch KA, Lazaridis KN. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: Evidence for a gene-gene interaction. Hepatology 52(1):223-229, 2010. Mace EM, Zhang J, Siminovitch KA, Takei F. Elucidation of LFA-1- mediated signaling pathway of actin polarization in natural killer cells. Blood 116(8):1272-9, 2010.

Department of Medicine Annual Report 2010-2011

124


Katherine Siminovitch Freudenberg J, Lee AT, Siminovitch KA, Amos CI, Ballard D, Li W, Gregersen PK. Locus category based analysis of a large genome-wide-association study of rheumatoid arthritis. Human Molecular Genetics 19(19):3863-72, 2010. Cannons JL, Wu JZ, Gomez-Rodriguez J, Zhang J, Dong B, Liu Y, Shaw S,Siminovitch KA, Schwartzberg PL. Biochemical and genetic evidence for a SAP-PKC-theta interaction contributing to IL-4 regulation. Journal of Immunology. 185(5):2819-27, 2010. Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L, Westra HJ, Fehrmann RSN, Kurreeman FAS, Thomson B, Gupta N, Romanos J, McManus R, Ryan AW, Turner G, Brouwer E, Posthumus MD, Remmers EF, Greco L, Toes R, Grandone E, Mazzilli MC, Rybak A, Cukrowska B, Coenen MJH, Radstake TRDJ, van Riel PLCM, Li Y, de Bakker PIW, Gregersen PK, Worthington J, Siminovitch KA, Klareskog L, Huizinga TWJ, Wijmenga C, Plenge RM. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genetics

Review Articles Hirschfield GM, Amos CI, Siminovitch KA. Navigating the road to personalized medicine: Can we believe? Canadian Medical Association Journal 182(7):651-2, 2010.

Department of Medicine Annual Report 2010-2011

125


Hillary Steinhart Gastroenterology Publications for 2010 PEER REVEIEWED Original Research and Systemic Reviews Turner D, Griffiths AM, Mack D, Otley AR, Seow CH, Steinhart AH, Silverberg MS, Hyams J, Guyatt GH. . Assessing disease activity in ulcerative colitis: Patients or their physicians? Inflamm Bowel Dis. 2010 Apr;16(4):651-6. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010 Jan;59(1):49-54. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010 Jan 20; (1):CD004115. Published Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D’Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EMM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, Steinwurz F, Vatn MH, Yamamoto-Furusho JK. Proceedings of the World Digestive Health Day 2010 - Inflammatory Bowel Disease Task Force Group at the Annual American Gastroenterological Association (AGA) Meeting. Inflammatory Bowel Diseases 2010 Barber C, Lee P, Steinhart AH, Lazarou J. Multifocal Motor Neuropathy with Conduction Block Following Treatment with Infliximab. J Rheum 2010;37:1778-80 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5- aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010 Jan 20; 1):CD004115.

NON PEER REVEIEWED Steinhart AH. Steroid therapy for Crohn’s disease. In: More Clinical Dilemmas in Inflammatory Bowel Disease. Irving P, Siegel C, Rampton D, Shanahan F (ed.) Wiley Blackwell Publications , Oxford, 2010.

Other Silverberg MS, Rubin DT, Steinhart AH, Cohen LB, Rotter JI. Israel-Gaza conflict. Lancet. 2009 Mar 14;373(9667):891-2.

Department of Medicine Annual Report 2010-2011

126


Thomas Stewart Respirology External Research Grants Prepared July 2011 Research Area

Role

Granting Agency

Funding

Period

Outcomes of Critically Ill Patients Presenting to Canadian Emergency Departments. CIHR Partnerships for Health System Improvement

Co-Investigstor

CIHR

$172,451

2009-2010

Department of Medicine Annual Report 2010-2011

127


Thomas Stewart Respirology Publications for 2010 PEER REVEIEWED Journal Articles Raboud JM, Shigayeva A, McGeer A, Bontovics E, Chapman M, Gravel D, Henry B, Lapinsky S, Loeb M, McDonald C, Ofner M, Paton S, Reynolds D, Scales D, Shen S, Simor AE, Stewart TE, Verncombe M, Zoutman D, Green K. Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. PLoS One. 2010 May 19;5(5):e10717. Morris AM, Stewart TE, Shandling M, McIntaggart S, Liles WC. Establishing an antimicrobial stewardship program. Healthcare Quarterly 2010;13(2):64-70. Briel M, Meade M, Mercat A, Brower RG, Slutsky AS, Walter SD, Talmor D, Pullenayegum E, Zhou Q, Cook D, Brochard L, Richard JCM, Guyatt G, Bhatnagar N, Stewart TE, Lamontagne F. Higher versus lower positive endexpiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysis. JAMA 2010;303(09):865-873. Morris AM, Liles WC, Stewart TE. Antimicrobial Stewardship in the Design of Critical Care. International Journal of Intensive Care. Freed DH, Henzler D, White CW, Fowler R, Zarychanski R, Hutchison J, Arora RC, Manji RA, Legare JF, Drews T, Veroukis S, Kesselman M, Guerguerian AM, Kumar A, the Canadian Critical Care Trials Group. Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) 2009 infection in Canada. Can J Anesth/J Can Anesth DOI 10.1007/s12630-009-9253-0.

Book Chapters Chou Liang Mah, Niall D. Ferguson, Thomas E. Stewart, Sangeeta Mehta. Chapter 69 – High Frequency Ventilation

Department of Medicine Annual Report 2010-2011

128


Bernard Zinman Endocrinology External Research Grants Prepared July 2011 Research Area Insulin resistance and beta-cell dysfunction in early childhood: the role of maternal and infant metabolic risk factors Longitudinal associations of adipocytokines and markers of sub-clinical inflammation with changes in insulin resistance and beta-cell function women with a history of gestational diabetes Epidemiology of Diabetes Interventions and Complications A Canadian Avandament® Normoglycemia Outcomes Evaluation Study The Sandy Lake Health and Diabetes Project: Understanding and Addressing Metabolic Syndrome, Diabetes and Associated Complications in Aboriginal Canadians The impact of dietary factors on the pathophysiology of gestational diabetes and subsequent type 2 diabetes

Role

Granting Agency

Funding

Period

Co-Investigator

CIHR

$440,000

2008 – 2013

Co-Investigator

CIHR

$744,845

2007 – 2012

PI

NIH

$106,000/yr

2006 – 2016

PI

GlaxoSmithKline

$2,088,377

2004 – 2010

Co-Investigator

CIHR

$1,073,870

2006 - 2011

Co-Investigator

Canadian Diabetes Association

$272,590

2008 - 2011

Department of Medicine Annual Report 2010-2011

129


Bernard Zinman Research Area Role of the Arginine/nitric oxide metabolome in the early natural history of cardiovascular disease in young women with varying degrees of glucose intolerance in pregnancy. Impact of maternal metabolic syndrome abnormalities in pregnancy on breast milk composition and subsequent infant metabolic development The early natural history of cardiovascular disease at 4-years postpartum in young women with varying degrees of glucose intolerance in pregnancy The MiTY Trial (Metformin in women with Type 2 diabetes in pregnancy).

Role

Granting Agency

Funding

Period

PI

Canadian Diabetes Association

$274,991

2010-2013

Co-Investigator

CDA

$255,000

2009 - 2012

Co-Investigator

Heart and Stroke Foundation of Canada

$180,000

2009 - 2012

Co-I

CIHR

$1,735,119

2010-2015

Department of Medicine Annual Report 2010-2011

130


Bernard Zinman Research Area Development of a sensitive non-invasive biothermophotonic device for blood glucose monitoring in patients with diabetes (WavelenghtModulated Differential Photothermal Radiometer) Role of the Arginine/nitric oxide metabolome in the early natural history of cardiovascular disease in young women with varying degrees of glucose intolerance in pregnancy

Role

Granting Agency

Funding

Period

Co-I

NSERC

$297,504

2007-2010

Co-Investigator

CIHR

$88,000

2010-2011

Department of Medicine Annual Report 2010-2011

131


Bernard Zinman Endocrinology Publications for 2010 PEER REVIEWED Original Research and Systematic Reviews Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B for A Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone decreases C-Reactive Protein to a greater extent relative to Glyburide and Metformin over four years despite greater weight gain. Diabetes Care 33(1): 177-183, 2010. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 12(1): 65-71, 2010. Zinman B, Haffner S, Herman W, Holman R, Lachin J, Kravitz B, Paul G, Jones NP, Aftring RP, Viberti G, Kahn S, for the ADOPT Study Group. Effect of rosiglitazone, metformin and glyburide on bone biomarkers in patients with Type 2 diabetes. JCEM 95(10): 134-142, 2010. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated Type 1 diabetes. A pilot study. Diabetes Care 33(2): 361-365, 2010. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. Low adiponectin concentration during pregnancy predicts postpartum insulin resistance, beta-cell dysfunction and fasting glycemia. Diabetologia 53(2): 268-276, 2010. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HG, for the DREAM Study Investigators. Effect of rosiglitazone and ramipril on beta-cell function in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 33(3): 608-613, 2010. Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, Hegele RA, Zinman B, Hanley AJ. Association of apolipoproteins B with incident Type 2 diabetes in an Aboriginal Canadian population. Clin Chem 56(4): 666-670, 2010. Klein R, Myers CE, Klein BE, Zinman B, Gardiner R, Suissa S, Sinaiko AR, Donnelly SM, Goodyer P, Strand T, Mauer M. Relationship of blood pressure to retinal vessel diameter in Type 1 diabetes. Arch Ophthalmol 128(2): 198-205, 2010. AhrĂŠn B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S, Fonseca VA. Changes in prandial glucagon levels after a two-year treatment with Vildagliptin or Glimepiride in patients with Type 2 diabetes inadequately controlled with Metformin monotherapy. Diabetes Care 33(4): 730-732, 2010. Zinman B, Harris S, Neuman J, Gerstein H, Retnakaran R, Raboud J, Qi Y, Hanley A. Low-dose combination therapy with rosiglitazone and metformin to prevent Type 2 DM (CANOE trial): a doubleblind randomized controlled study. The Lancet 376(9735): 103-111, 2010. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, Perkins BA, Harris SB, Zinman B, Hanley AJ. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes mellitus. Diabetes Care 33(6): 1379-1381, 2010.

Department of Medicine Annual Report 2010-2011

132


Bernard Zinman Cherney DZ, Reich HN, Miller JA, Lai V, Zinman B. Dekker MG, Bradley TJ, Scholey JW, Sochett EB. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated Type 1 diabetes mellitus. AJP Regul Integr Comp Physiol 299(1): R206-R214, 2010. Fonseca VA, Zinman B, Nauck MA, Goldfine AB, Plutzky J. Confronting the Type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am J Med 123(7): S2-S10, 2010. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J, for the EDIC Study group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33(7): 1536-1543, 2010. Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B. Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 33(8):1798-1804, 2010. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 12(9): 780789, 2010. Ley S, Hegele R, Connelly P, Harris S, Mamakeesick M, Cao H, Gittelsohn J, Retnakaran R, Zinman B, Hanley AJ. Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. Cardiovasc Diab 9:39, 2010. Retnakaran R, Qi Y, Connelly PW, Sermer M, Hanley AJ, Zinman B. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of LDL cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk. JCEM 95:4345-53, 2010. Kew S, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zinman B, Retnakaran R. Relationship between short stature and postchallenge glycemia in pregnancy. Diabetes Care 33(12): e173, 2010. Teoh H, Braga MF, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan MK, Ur E, Yan AT, Zinman B, Leiter LA on behalf the T2DM QUERI Investigators. Type 2 Do More Quality Enhancement Research Initiative (T2DM QUERI): Patient age, ethnicity, medical history and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets. Diabetes Care 33(12): 2558-2560, 2010. Ley SH, O’Connor DL, Retnakaran R, Hamilton JK, Sermer M, Zinman B, Hanley AJ. Impact of maternal metabolic abnormalities in pregnancy on human milk and subsequent infant metabolic development: methodology and design. BMC Public Health 10: 590, 2010. Kayaniyil S, Vieth R, Harris SB, Retnakaran R, Knight JA, Gerstein HC, Perkins BA, Zinman B, Hanley AJ. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. JCEM 96(1): 168-175, 2010. Retnakaran R, Qi Y, Connelly PW, Sermer M, Zinman B, Hanley AJ. Glucose intolerance in pregnancy and postpartum risk of metabolic syndrome in young women. JCEM 95: 670-677, 2010.

Department of Medicine Annual Report 2010-2011

133


testing